Bion Environmental (BNET) 10-K 22 Sep 15 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2015	Sep. 01, 2015	Dec. 31, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	BION ENVIRONMENTAL TECHNOLOGIES INC
Trading Symbol	bnet
Document Type	10-K
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding		21,760,502
Entity Public Float			$ 4,600,000
Amendment Flag	false
Entity Central Index Key	875,729
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Current assets:
Cash	$ 339,286	$ 186,148
Prepaid expenses	18,503	17,006
Subscription receivable (Note 9)	13,125	30,000
Deposits and other receivables	7,108	7,108
Total current assets	378,022	240,262
Property and equipment, net (Note 3)	1,977,219	4,351,153
Total assets	2,355,241	4,591,415
Current liabilities:
Accounts payable and accrued expenses	1,353,168	1,434,381
Loans payable - affiliates (Note 4)		382,458
Notes payable - affiliates, net of discount (Note 5)	472,230
Deferred compensation (Note 6)	839,288	716,734
Convertible notes payable - affiliates, current (Note 8)		1,736,502
Loan payable (Note 7)	7,754,000	7,754,000
Total current liabilities	10,444,086	12,047,475
Convertible notes payable - affiliates, net of current portion (Note 8)	2,654,708
Total liabilities	13,098,794	12,047,475
Bion's stockholders' equity (deficit):
Common stock, no par value, 100,000,000 shares authorized, 22,089,650 and 19,576,619 shares issued, respectively; 21,385,341 and 18,872,310 shares outstanding, respectively	0	0
Additional paid-in capital	100,889,127	98,537,032
Accumulated deficit	(111,696,060)	(106,067,869)
Total Bion's stockholders’ deficit	(10,806,933)	(7,530,837)
Noncontrolling interest	63,380	74,777
Total deficit	(10,743,553)	(7,456,060)
Total liabilities and deficit	2,355,241	4,591,415
Series B Preferred Stock [Member]
Current liabilities:
Series B Redeemable Convertible Preferred stock, $0.01 par value, 50,000 shares authorized; 200 shares issued and outstanding, liquidation preference of $28,000 and $26,000, respecitvely	25,400	23,400
Series A Preferred Stock [Member]
Bion's stockholders' equity (deficit):
Preferred stock	0	0
Series C Preferred Stock [Member]
Bion's stockholders' equity (deficit):
Preferred stock	$ 0	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2015	Jun. 30, 2014
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	22,089,650	19,576,619
Common stock, shares outstanding	21,385,341	18,872,310
Common stock, par value (in Dollars per share)	$ 0	$ 0
Series B Preferred Stock [Member]
Par value (in Dollars per share)	$ 0.01	$ 0.01
Shares authorized	50,000	50,000
Shares issued	200	200
Shares outstanding	200	200
Liquidation preference (in Dollars per share)	$ 28,000	$ 26,000
Series A Preferred Stock [Member]
Par value (in Dollars per share)	$ 0.01	$ 0.01
Shares authorized	10,000	10,000
Shares issued	0	0
Shares outstanding	0	0
Series C Preferred Stock [Member]
Par value (in Dollars per share)	$ 0.01	$ 0.01
Shares authorized	60,000	60,000
Shares issued	0	0
Shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - Scenario, Unspecified [Domain] - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Revenue	$ 3,658	$ 5,931
Operating expenses:
General and administrative (including stock-based compensation (Note 9))	2,375,145	2,269,045
Depreciation	623,934	978,798
Impairment loss on property and equipment	1,750,000	2,000,000
Research and development (including stock-based compensation (Note 9))	520,462	134,862
Total operating expenses	5,269,541	5,382,705
Loss from operations	(5,265,883)	(5,376,774)
Other expense:
Interest expense	373,705	403,410
Gain on extinguishment of liabilities		(20,113)
Other expense		1,918
	373,705	385,215
Net loss	(5,639,588)	(5,761,989)
Net loss attributable to the noncontrolling interest	11,397	2,976
Net loss attributable to Bion	(5,628,191)	(5,759,013)
Conversion inducement (Note 9)	(9,593)
Dividends on preferred stock	(2,000)	(2,000)
Net loss applicable to Bion's common stockholders	$ (5,639,784)	$ (5,761,013)
Net loss applicable to Bion's common stockholders per basic and diluted common share (in Dollars per share)	$ (0.27)	$ (0.31)
Weighted-average number of common shares outstanding:
Basic and diluted (in Shares)	20,545,456	18,636,364

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity (Deficit) - USD ($)	Series B Preferred Stock [Member]Additional Paid-in Capital [Member]	Series B Preferred Stock [Member]	Common Stock [Member]Stock Issued to Satisfy Accounts Payable [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]Stock Issued to Satisfy Accounts Payable [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Stock Issued to Satisfy Accounts Payable [Member]	Total
Balances, amount at Jun. 30, 2013						$ 96,829,488	$ (100,308,856)	$ 77,753		$ (3,401,615)
Balances, shares (in Shares) at Jun. 30, 2013				17,673,983
Vesting of options for services						(204,257)				(204,257)
Issuance of common stock for services, amount						307,102				$ 307,102
Issuance of common stock for services, shares (in Shares)				360,066						360,066
Issuance of common stock to satisfy accounts payable					$ 19,940				$ 19,940
Issuance of common stock to satisfy accounts payable (in Shares)			13,369
Modification of options						307,638				$ 307,638
Issuance of warrants for services, interest, and commissions						14,046				14,046
Sale of common stock, amount						967,575				967,575
Sale of common stock, shares (in Shares)				1,279,201
Dividend on preferred stock	$ (2,000)	$ (2,000)
Conversion, amount						297,500				$ 297,500
Conversion, shares (in Shares)				250,000						250,000
Net loss							(5,759,013)	(2,976)		$ (5,761,989)
Balances, amount at Jun. 30, 2014						98,537,032	(106,067,869)	74,777		(7,456,060)
Balances, shares (in Shares) at Jun. 30, 2014				19,576,619
Vesting of options for services						501,609				501,609
Issuance of common stock for services, amount						41,028				$ 41,028
Issuance of common stock for services, shares (in Shares)				120,647						45,647
Modification of options						369,283				$ 369,283
Issuance of warrants for services, interest, and commissions						72,118				72,118
Modification of warrants						230,636				230,636
Sale of common stock, amount						26,250				26,250
Sale of common stock, shares (in Shares)				75,000
Sale of units						900,000				900,000
Sale of units (in Shares)				1,800,000
Commissions on sale of units						(61,522)				(61,522)
Warrants exercised for common stock						87,815				87,815
Warrants exercised for common stock (in Shares)				71,133
Dividend on preferred stock	$ (2,000)	$ (2,000)
Conversion, amount						186,878				186,878
Conversion, shares (in Shares)				466,251
Cancellation of common stock (in Shares)				(20,000)
Net loss							(5,628,191)	(11,397)		(5,639,588)
Balances, amount at Jun. 30, 2015						$ 100,889,127	$ (111,696,060)	$ 63,380		$ (10,743,553)
Balances, shares (in Shares) at Jun. 30, 2015				22,089,650

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (5,639,588)	$ (5,761,989)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on disposal of property and equipment		1,919
Depreciation expense	623,934	978,798
Impairment loss on property and equipment	1,750,000	2,000,000
Accrued interest on deferred compensation and other	412,383	360,326
Stock-based compensation	1,142,556	397,780
(Increase) decrease in prepaid expenses	(1,497)	27,806
Increase in deposits and other receivables		(1,000)
(Decrease) increase in accounts payable and accrued expenses	(128,572)	287,280
Increase in deferred compensation and convertible notes	1,030,784	728,400
Decrease in deferred rent		(10,929)
Net cash used in operating activities	(810,000)	(991,609)
CASH FLOWS FROM INVESTING ACTIVITIES
Release of restricted cash		57,315
Purchase of property and equipment		(850)
Net cash provided by investing activities		56,465
CASH FLOWS FROM FINANCING ACTIVITIES
Decrease in subscription receivable	30,000	25,000
Proceeds from sale of common stock	26,250	944,400
Proceeds from sale of units	893,720
Proceeds from exercise of warrants	74,690
Share issuance costs	(61,522)	(6,825)
Proceeds from loans payable - affiliates		185,149
Payment of loans payable - affiliates		(71,098)
Net cash provided by financing activities	963,138	1,076,626
Net increase in cash	153,138	141,482
Cash at beginning of period	186,148	44,666
Cash at end of period	339,286	186,148
Supplemental disclosure of cash flow information:
Cash paid for interest		1,098
Non-cash investing and financing transactions:
Issuance of common stock to satisfy deferred compensation	80,780	26,749
Issuance of common stock to satisfy accounts payable		19,940
Conversion of debt to equity	112,379	297,500
Subscription receivable	13,125	30,000
Series B Preferred Stock [Member]
Non-cash investing and financing transactions:
Series B preferred stock dividends accrued	$ 2,000	$ 2,000

Note 1 - Organization, Nature o

Note 1 - Organization, Nature of Business, Going Concern and Management's Plans	12 Months Ended
	Jun. 30, 2015
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS: Organization and nature of business: Bion Environmental Technologies, Inc. (“Bion” or “We” or the "Company") was incorporated in 1987 in the State of Colorado and has developed and continues to develop patented and proprietary technology and business models that provide comprehensive environmental solutions to a significant source of pollution in United States agriculture, large scale livestock facilities known as Confined Animal Feeding Operations ("CAFO's"). Bion's technologies (and applications related thereto) produce substantial reductions of nutrient releases (primarily nitrogen and phosphorus) to both water and air (including ammonia, which is subsequently re-deposited to the ground) from livestock waste streams based upon our operations and research to date (and third party peer review thereof). We are continually involved in research and development to upgrade and improve our technology and technology applications, including integration with third party technology. Bion provides comprehensive and cost-effective treatment of livestock waste onsite, while it is still concentrated and before it contaminates air, soil, groundwater aquifers and/or downstream waters, and, in certain configurations, recovers nutrients for potential use as fertilizer and feed additives. During the 2014 fiscal year the Company increased its research and development activities with focus on creating variations of its technology platform that provide additional flexibility, increase recovery of nutrient by-products (in organic and non-organic forms) and potential related revenue streams, and to review potential “add-ons” and applications for use in different regulatory environments. These research and development activities continued through the 2015 fiscal year, and we believe such activities will continue at least through the 2016 fiscal year, subject to availability of adequate financing for the Company’s operations, of which there is no assurance. Bion is actively pursuing business opportunities in three broad areas 1) installation of Bion systems to retrofit and environmentally remediate existing CAFO’s to reduce nutrient (primarily nitrogen and phosphorus) releases, gaseous emissions (ammonia, greenhouse gases, volatile organic compounds, etc.), and pathogens, hormones and other compounds in order to clean the air and water in the surrounding areas (as described below) to ensure compliance with existing (and future) regulations and to permit herd expansion; 2) development of Integrated Projects opportunities within the United States and internationally; and 3) licensing and/or joint venturing of Bion’s technology and applications outside North America. The opportunities described at 1) and 2) above (and below) each require substantial political and regulatory (federal, state and local) efforts on the part of the Company and a substantial part of Bion’s efforts are focused on such political and regulatory matters. The most intense focus is currently on the requirements for the clean-up of the Chesapeake Bay faced by the Commonwealth of Pennsylvania and the potential use of Bion’s technology on CAFOs as an alternative to what the Company believes is far more expensive nutrient removal downstream in stormwater projects. Management believes that Bion's technology platform (including utilization of various third party technologies to supplement the Company’s proprietary technologies), in addition to utilization for remediation of the waste streams of existing CAFOs, can enable the integration of large-scale CAFO's and their end-product users, renewable energy production from the CAFO waste stream, on site utilization of the renewable energy generated and biofuel/ethanol production in an environmentally and economically sustainable manner while reducing the aggregate capital expense and operating costs for the entire integrated complex ("Integrated Projects" or "Projects"). In the context of Integrated Projects, Bion's waste treatment process, in addition to mitigating polluting releases, enables generation of renewable energy from cellulosic portions of the CAFO waste stream, which renewable energy can be utilized by integrated facilities including ethanol plants, CAFO end-product processors (including cheese, ice cream and/or bottling plants in the case of dairy CAFO’s and/or slaughter and/or processing facilities in the context of beef CAFO’s) and/or other users as a fossil fuel replacement. The nutrients (primarily nitrogen and phosphorus) can be harvested from the solids and liquid streams recovered from the livestock waste stream and can be utilized as either high value fertilizer and/or the basis for high protein animal feed and the nutrient rich effluent can potentially be utilized in integrated hydroponic agriculture and/or field applied as fertilizer. Bion believes that its Integrated Projects will produce high quality, traceable animal protein which can address consumer food safety/security concerns at a lower cost than current industry practices while also maintaining a far lower net environmental footprint per unit of protein produced due to water recycling (possible due to the removal of nutrients, etc. from the water by Bion’s technology applications), production of renewable energy from the waste stream (reducing the use of fossil fuels), and multiple levels of economies of scale, co-location and integration savings in transportation and other logistics. Some projects may involve only partial integration which will limit the benefits described herein. On September 27, 2008, the Company executed an agreement with Kreider Farms (and its affiliated entities) (collectively "Kreider") to design, construct and operate (through its wholly-owned subsidiaries, Bion Services Group, Inc. (“Bion Services”) and Bion PA-1 LLC (“PA-1”) a Bion system to treat the waste of 1,200 milking dairy cows (milkers, dry cows and heifers) at the Kreider Dairy, located in Manheim, Pennsylvania. In addition, the agreement (as amended and supplemented) provides for a second phase which will treat the wastes from the rest of Kreider’s herd and includes renewable energy production from the cellulosic solid wastes from the Phase 1 system (referred to as “Kreider 1”) together with the waste stream from Kreider’s poultry facilities for use at the facilities and/or for market sales. The Kreider projects are owned and operated by Bion through subsidiaries, in which Kreider has the option to purchase a noncontrolling interest. To complete these projects, substantial capital (equity and/or debt) has been and will continue to be expended. Additional funds will be required for continuing operations of Kreider 1 until sufficient revenues can be generated, of which there is no assurance. The Company anticipates that such projects will generate revenue primarily from the sale of nutrient reduction (and/or other) environmental credits related to Kreider 1 and the Kreider Phase 2 poultry waste treatment system (not yet constructed), and secondarily through sales of byproducts (feed additives and/or fertilizer, (organic and non-organic)) and renewable energy generated by the Kreider Phase 2 system. To date the market for long-term nutrient reduction credits in Pennsylvania has been very slow to develop and the Company’s activities have been negatively affected by the lack of such development. A portion of Bion’s research and development activities is currently taking place at the Kreider 1 facility. The Company’s subsidiary PA-1 financed Kreider 1 through a $7.8 million loan (“Pennvest Loan”) from Pennsylvania Infrastructure Investment Authority (“Pennvest”) secured by Kreider 1 (and its revenue streams, if any) plus advances from the Company. The economics (potential revenues and profitability) of Kreider 1 are based largely on the long-term sale of nutrient reduction credits (nitrogen and/or phosphorus) to meet the requirements of the Chesapeake Bay environmental clean-up. The Pennsylvania Department of Environmental Protection (“PADEP”) issued final permits for Kreider 1 (including the credit verification plan) on August 1, 2012 on which date the Company deemed that Kreider 1 was ‘placed in service’. However, liquidity in the Pennsylvania nutrient credit market has been slow to develop significant breadth and depth and has prevented Bion from monetizing the nutrient reduction credits created by PA-1’s Kreider 1 project and Bion’s other proposed projects. These challenges and difficulties raise significant questions as to when PA-1 will be able to generate such revenues from Kreider 1. PA-1 has elected not to make interest or principal payments on the Pennvest Loan since January 2013 and, therefore, the Company has classified the Pennvest Loan as a current liability as of June 30, 2015. The Company also recorded a $1,750,000 impairment of the Kreider 1 assets for the year ended June 30, 2015 (following a $2,000,000 impairment during the year ended June 30, 2014) which reduced the value of the Kreider 1 System to $1,976,621 as of June 30, 2015 (see Note 3). On September 25, 2014, Pennvest exercised its right to declare the Pennvest Loan in default and has accelerated the Pennvest Loan and demanded that PA-1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA-1 did not make the payment and does not have the resources to make the payment demanded by Pennvest. PA-1 has commenced discussions and negotiations with Pennvest concerning this matter but Pennvest has rejected PA-1’s proposal made during the fall of 2014. Neither party has any formal proposal on the table as of the date of this report but discussions and negotiations remain in process. It is not possible at this date to predict the outcome of such negotiations, but the Company believes that an agreement may yet be reached that will provide a loan modification. Subject to the results of the negotiations with Pennvest and pending development of a more robust market for nutrient reductions in Pennsylvania, PA-1 and Bion will continue to evaluate various options with regard to Kreider 1 over the next 30-180 days. During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan is now solely an obligation of PA-1. Development work and technology evaluation, including amended credit certification and discussions with potential joint venture partners, continues related to the details of the second phase of the Kreider project which primarily relates to treatment of the wastes from Kreider’s poultry operations. Assuming there are positive developments related to the market for nutrient reduction in Pennsylvania, the Company intends to pursue development, design and construction of the Kreider 2 poultry waste/renewable energy project with a goal of achieving operational status during calendar year 2016. However, as discussed above, this project faces challenges related to the current limits of the existing nutrient reduction market and funding of technology-based, verifiable agricultural nutrient reductions. A significant portion of Bion’s activities concern efforts with private and public stakeholders (at local and state level) in Pennsylvania (and other Chesapeake Bay and Midwest and Great Lakes states) and at the federal level (the Environmental Protection Agency (“EPA”) (and other executive departments) and Congress) to establish appropriate public policies which will create regulations and funding mechanisms that foster installation of the low cost environmental solutions that Bion (and others) can provide through clean-up of agricultural waste streams. The Company anticipates that such efforts will continue in Pennsylvania throughout the next 12 months and in various additional states thereafter. Going concern and management’s plans: The consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and has incurred net losses (including significant non-cash expenses) of approximately $5,640,000 and $5,762,000 during the years ended June 30, 2015 and 2014, respectively. At June 30, 2015, the Company has a working capital deficit and a stockholders’ deficit of approximately $10,066,064 and $10,807,000, respectively. These factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions. The Company continues to explore sources of additional financing to satisfy its current operating requirements as it is not currently generating any significant revenues. During the years ended June 30, 2015 and 2014, the Company received total proceeds of $1,000,940 and $944,400, respectively, from the sale of its equity securities (Note 9). Proceeds during the 2015 and 2014 fiscal years have been lower than in earlier years and accordingly has negatively impacted the Company’s business development efforts. During fiscal years 2015 and 2014, the Company experienced greater difficulty in raising equity funding than in the prior years. As a result, the Company faced, and continues to face, significant cash flow management challenges due to working capital constraints. To partially mitigate these working capital constraints, the Company’s core senior management and several key employees and consultants have been deferring (and continue to defer) all or part of their cash compensation and/or are accepting compensation in the form of securities of the Company (Notes 6 and 8) and members of the Company’s senior management have made loans to the Company (Note 4). Additionally, the Company made reductions in its personnel during the year ended June 30, 2014. The constraint on available resources has had, and continues to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company does not have greater success in its efforts to raise needed funds during the balance of the 2015 calendar year (and subsequent periods), management will need to consider deeper cuts (including additional personnel cuts) and curtailment of operations (including possibly Kreider 1 operations) and/or research and development activities. The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Integrated Projects and CAFO waste remediation systems (including the Kreider 2 facility) and to continue to operate the Kreider 1 facility. The Company anticipates that it will seek to raise from $2,500,000 to $50,000,000 or more debt and/or equity through joint ventures and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in recent periods and the extremely unsettled capital markets that presently exist (especially for small companies), that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and projects. There is no realistic likelihood that funds required during the next twelve months or in the periods immediately thereafter for the Company’s basic operations and/or proposed projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company's existing shareholders. All of these factors have been exacerbated by the extremely unsettled credit and capital markets presently existing for small companies like Bion.

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. SIGNIFICANT ACCOUNTING POLICIES Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc. (“Projects Group”), Bion Technologies, Inc., BionSoil, Inc., Bion Services, PA-1, and Bion PA 2 LLC; and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation. Cash: The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash. Property and equipment: Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations. Derivative Financial Instruments: Pursuant to Accounting Standards Codification (“ASC”) Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative assets or liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. Warrants: The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined. Concentrations of credit risk: The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts. Noncontrolling interests: In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance. Fair value measurements: Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value. Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 – assets and liabilities whose significant value drivers are unobservable. Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable approximates its carrying amount as it bears interest at rates commensurate with market rates. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of deferred compensation, notes payable - affiliates and loans payable – affiliates are not practicable to estimate due to the related party nature of the underlying transactions. Revenue Recognition: Revenues are generated from the sale of nutrient reduction credits. The Company recognizes revenue from the sale of nutrient credits when there is persuasive evidence that an arrangement exists, when title has passed, the price is fixed or determinable, and collection is reasonably assured. The Company expects that technology license fees will be generated from the licensing of Bion’s integrated system. The Company anticipates that it will charge its customers a non-refundable up-front technology license fee, which will be recognized over the estimated life of the customer relationship. In addition, any on-going technology license fees will be recognized as earned based upon the performance requirements of the agreement. Annual waste treatment fees will be recognized upon receipt. Revenues, if any, from the Company’s interest in Integrated Projects will be recognized when the entity in which the Integrated Project has been developed recognizes such revenue. Stock-based compensation: The Company recognizes the cost of employee services received in exchange for an award of equity instruments in the financial statements and the cost is measured based on the grant date fair value of the award. The stock option compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (the requisite service period). The Company utilizes the Black-Scholes option-pricing model to determine fair value. Key assumptions of the Black-Scholes option-pricing model include applicable volatility rates, risk-free interest rates and the instrument’s expected remaining life. These assumptions require significant management judgment. The Company has issued non-employee options that include service conditions and have graded vesting schedules. Generally for these arrangements, the measurement date of the services occurs when the options vest. Recognition of compensation cost for reporting periods prior to the measurement date is based on the then current fair value of the options. Fair value of the options is determined using a Black-Scholes option-pricing model. Any subsequent changes in fair value will be recorded on the measurement date. Compensation cost in connection with options that are not fully vested is being recognized on a straight-line basis over the requisite service period for the entire award. Income taxes: The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases, as well as net operating losses. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets or liabilities of a change in tax rates is recognized in the period in which the tax change occurs. A valuation allowance is provided to reduce the deferred tax assets by 100%, since the Company believes that at this time it is more likely than not that the deferred tax asset will not be realized. The Company is no longer subject to U.S. federal and state tax examinations for fiscal years before 2009. Management does not believe there will be any material changes in the Company’s unrecognized tax positions over the next 12 months. The Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. As of June 30, 2015, there were no penalties or accrued interest amounts associated with any unrecognized tax benefits, nor was any interest expense recognized during the years ended June 30, 2015 and 2014. Loss per share: Basic loss per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted loss per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the loss per share. During the years ended June 30, 2015 and 2014, the basic and diluted loss per share was the same, as the impact of potential dilutive common shares was anti-dilutive. The following table represents the warrants, options and convertible securities excluded from the calculation of diluted loss per share: June 30, 2015 June 30, 2014 Warrants 9,532,189 7,622,653 Options 4,413,870 4,258,870 Convertible debt 6,056,270 2,820,157 Convertible preferred stock 14,000 13,000 The following is a reconciliation of the denominators of the basic loss per share computations for the years ended June 30, 2015 and 2014: Year ended June 30, 2015 Year ended June 30, 2014 Shares issued – beginning of period 19,576,619 17,673,983 Shares held by subsidiaries (Note 9) (704,309 ) (704,309 ) Shares outstanding – beginning of period 18,872,310 16,969,674 Weighted average shares for fully vested stock bonuses (Note 9) 675,000 840,000 Weighted average shares issued during the period 998,146 826,690 Basic weighted average shares – end of period 20,545,456 18,636,364 Reclassifications: Certain amounts in the prior year financial statements have been reclassified to conform to the current year presentation. Use of estimates: In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Recent Accounting Pronouncements: The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s financial statements properly reflect the change. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09 “Revenue from Contracts from Customers,” which supersedes the revenue recognition requirements in “Revenue Recognition (Topic 605),” and requires entities to recognize revenue in a way that depicts the transfer of potential goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to the exchange for those goods or services. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017 and early adoption is not permitted. The Company is currently evaluating the new standard and assessing the potential impact on its operations and financial statements. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements – Going Concern: Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. The guidance is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early application is permitted. The Company believes that the adoption of ASU No. 2014-15 will not have a material impact on its financial statements.

Note 3 - Property and Equipment

Note 3 - Property and Equipment	12 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	3. PROPERTY AND EQUIPMENT: Property and equipment consists of the following: June 30, 2015 June 30, 2014 Machinery and equipment $ 2,923,577 $ 4,111,001 Buildings and structures 1,385,125 1,947,701 Computers and office equipment 175,248 183,809 4,483,950 6,242,511 Less accumulated depreciation (2,506,731 ) (1,891,358 ) $ 1,977,219 $ 4,351,153 Management reviewed property and equipment for impairment as of June 30, 2015 and determined that the carrying amount of property and equipment related to the Kreider 1 project exceeded its estimated future undiscounted cash flows based on certain assumptions regarding timing, level and probability of revenues from sales of nutrient reduction credits. Kreider 1 was measured at estimated fair value on a non-recurring basis using level 3 inputs, which resulted in an impairment of $1,750,000 of the property and equipment for the year ended June 30, 2015. The Company also recorded an impairment of $2,000,000 for the year ended June 30, 2014. Depreciation expense was $623,934 and $978,798 for the years ended June 30, 2015 and 2014, respectively.

Note 4 - Loans Payable - Affili

Note 4 - Loans Payable - Affiliates	12 Months Ended
	Jun. 30, 2015
Loans Payable - Affiliates [Member]
Note 4 - Loans Payable - Affiliates [Line Items]
Related Party Transactions Disclosure [Text Block]	4. LOANS PAYABLE - AFFILIATES: During the year ended June 30, 2015, the Company had outstanding loans payable, under multiple agreements, with Dominic Bassani (“Bassani”), the Company’s Chief Executive Officer (“CEO”), and with a major shareholder (“Shareholder”) of $316,131 and $80,764, respectively. The loans accrued interest at 8% per annum and had varying maturity dates, which had been extended multiple times due to the cash constraints of the Company. During the year ended June 30, 2014, in consideration for loans of $135,000 (“Warrant Loans”), the Company issued warrants to purchase 33,750 shares of the Company’s common stock at $0.85 per share until December 31, 2018. Additional warrants (in the same amount and terms) were issued upon each extension of the maturity date of the Warrant Loans. As a result of the two extensions during the year ended June 30, 2015, the Company issued 67,500 warrants to purchase 67,500 shares of the Company’s common stock at $0.85 per share and has recorded interest expense of $6,750. During February and March 2015, the Company entered into agreements with Bassani and Shareholder, respectively, whereby effective January 1, 2015, all loans payable (principal and interest) were transferred into notes payable and convertible notes payable. As of June 30, 2015, the loans payable – affiliates is nil. Interest expense related to the loans payable – affiliates was $14,436 and $22,433 for the years ended June 30, 2015 and 2014, respectively.
Notes Payable - Affiliates [Member]
Note 4 - Loans Payable - Affiliates [Line Items]
Related Party Transactions Disclosure [Text Block]	5. NOTES PAYABLE - AFFILIATES : During February and March 2015, the Company entered into promissory notes (“2015 Promissory Notes”), with effective dates of January 1, 2015, for initial principal amounts of $395,277, $15,956 and $80,764, with Bassani, Edward Schafer (“Schafer”), the Company’s Vice Chairman, and Shareholder, respectively. The 2015 Promissory Notes bear interest at 4% per annum and are payable on December 31, 2015. In connection with the 2015 Promissory Notes, Bassani and Schafer were issued 1.5 warrants for each dollar of initial principal to purchase a share of the Company’s common stock at the price of $1.00 per share until December 31, 2020 (“Coverage Warrants”) and Shareholder was issued 0.5 Coverage Warrants for each dollar of initial principal, for a total of 654,350 Coverage Warrants. The Coverage Warrants were deemed to have a fair value of $0.10 per warrant and, therefore, the 2015 Promissory Notes were deemed to be issued with original issue discounts of $53,342, $2,153 and $3,720, respectively, based upon the relative fair value of the warrants and the present value of the face value of the 2015 Promissory Notes. The original issue discounts will be accreted over the duration of the 2015 Promissory Notes. For the year ended June 30, 2015, accretion and interest on the 2015 Promissory Notes were $29,608 and $9,840 respectively. As of June 30, 2015, the total of the 2015 Promissory Notes, including accrued interest, was $472,230.

Note 6 - Deferred Compensation

Note 6 - Deferred Compensation	12 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	6 . DEFERRED COMPENSATION: The Company owes deferred compensation to various employees, former employees and consultants totaling $839,288 of June 30, 2015. Included in the deferred compensation balances as of June 30, 2015, are $187,542, $64,861 and $90,746 owed Bassani, Smith and Schafer, respectively, pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, would accrue interest at 4% per annum and could be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last 10 trading days of the immediately preceding month. The Company also owes various consultants, pursuant to various agreements, deferred compensation of $254,655 as of June 30, 2015 with similar conversion terms as those described above for Bassani, Smith and Schafer, with the exception that the interest accrues at 3% per annum. The Company also owes a former employee and a current employee $168,000 and $984, respectively, in deferred compensation which is convertible into 226,168 and 856 shares, respectively, of the Company’s common stock as of June 30, 2015. In addition, the Company owes a former employee $72,500, which is not convertible and is non-interest bearing. Effective January 1, 2015, pursuant to Schafer’s extension agreement, his deferred compensation of $243,750 was transferred into a new deferred compensation convertible promissory note (Notes 8 and 13). The Company owed Bassani deferred compensation of $239,250 including interest of $74,250, which was due and payable on July 1, 2014 but had been extended until April 15, 2015. The deferred compensation accrued interest at 10% per annum and was convertible into the Company’s restricted common stock at $1.50 per share. Effective January 1, 2015, the Company entered into an extension agreement with Bassani, whereby his $239,250 of deferred compensation was transferred into a new deferred compensation convertible promissory note (Notes 8 and 13).

Note 7 - Loan Payable

Note 7 - Loan Payable	12 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	7 . LOAN PAYABLE: As of June 30, 2015, PA-1, the Company’s wholly-owned subsidiary, owes $7,754,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System. The terms of the Pennvest Loan provide for funding of up to $7,754,000 which is to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrues interest at 2.547% for years 1 through 5 and 3.184% for years 6 through maturity. The Pennvest Loan requires minimum annual principal payments of approximately $574,000 in fiscal year 2013, $704,000 in fiscal year 2014, $723,000 in fiscal year 2015, $741,000 in fiscal year 2016, $760,000 in fiscal year 2017 and $4,252,000 thereafter. The Pennvest Loan is collateralized by the Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest is entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $197,494 for both of the years ended June 30, 2015 and 2014, respectively. As of June 30, 2015, the accrued interest and late charges related to the Pennvest Loan total $577,001. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market to date, PA-1 has commenced negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan. In the context of such negotiations, PA-1 has elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the Company has not made any principal payments, which were to begin in fiscal 2013, and, therefore, the Company has classified the Pennvest Loan as a current liability as of June 30, 2015. On September 25, 2014, Pennvest exercised its right to declare the Pennvest Loan in default and has accelerated the Pennvest Loan and demanded that PA-1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA-1 did not make the payment and does not have the resources to make the payment demanded by Pennvest. PA-1 has commenced discussions and negotiations with Pennvest concerning this matter but Pennvest has rejected PA-1’s proposal made during the fall of 2014. Neither party has any formal proposal as of the date of this report. Subsequent discussions/negotiations have not led to any resolution of the outstanding matters as of this date. It is not possible at this date to predict the outcome of such negotiations, but the Company believes that a loan modification agreement may be reached that will allow PA-1 and Pennvest time for the development of a more robust market for nutrient reductions in Pennsylvania, of which there is no assurance. PA-1 and Bion will continue to evaluate various options with regard to Kreider 1 over the next 30-180 days. In connection with the Pennvest Loan financing documents, the Company provided a ‘technology guaranty’ regarding nutrient reduction performance of Kreider 1 which was structured to expire when Kreider 1’s nutrient reduction performance had been demonstrated. During August 2012 the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 System had surpassed the requisite performance criteria and that the Company’s ‘technology guaranty’ was met. As a result, the Pennvest Loan is solely an obligation of PA-1.

Note 8 - Convertible Notes Paya

Note 8 - Convertible Notes Payable - Affiliates	12 Months Ended
	Jun. 30, 2015
Convertible Debt [Abstract]
Convertible Debt [Text Block]	8 . CONVERTIBLE NOTES PAYABLE - AFFILIATES: Effective May 15, 2013, the Board of Directors approved agreements with Bassani and Smith, under which, Bassani and Smith agreed to continue to defer their cash compensation up to April 30, 2014 (unless the Board of Directors elects to re-commence cash payment on an earlier date) and to extend the due date of their deferred cash compensation until January 15, 2015. The Company’s obligations pursuant to these agreements were evidenced in the form of convertible promissory notes (“Convertible Notes”). During the year ended June 30, 2014, Bassani and Smith agreed to continue to defer their cash compensation up to July 1, 2014 and during September 2014, Bassani and Smith agreed to continue to defer their cash compensation up to January 1, 2015. During January 2015, Bassani and Smith agreed to continue to defer their cash compensation until April 15, 2015. During February 2015, Bassani and Smith entered into extension agreements with the Company whereby their Convertible Note balances owed as of December 31, 2014, subject to amounts already converted pursuant to their terms, were transferred to new convertible promissory notes (“2015 Convertible Notes”) and the Convertible Notes were cancelled (Note 13). Convertible Notes The Convertible Notes accrued interest at 8% per annum and were due and payable (as extended) on April 15, 2015. The Convertible Notes (including accrued interest) of $854,316 and $1,188,165 at December 31, 2014 owed to Smith and Bassani, respectively, plus all future deferred compensation or other sums subsequently added to the principal of the Convertible Notes, were convertible, at the sole election of Smith and Bassani, into Units consisting of one share of the Company’s common stock and one warrant to purchase a share of the Company’s common stock, at a price of $0.45 per Unit until January 15, 2015. The warrant contained in the Unit were to be exercisable at $2.50 per share until December 31, 2018. The original conversion price of $1.25 per Unit approximated the fair value of the Units at the date of the agreements; therefore no beneficial conversion feature exists. Pursuant to the deferral agreements, the conversion price of the Convertible Notes plus accrued interest was the lower of the $1.25 per Unit price or the lowest price at which the Company sells its common stock on or before January 15, 2015. As of December 31, 2014, the lowest price at which the Company had sold its common stock during the relevant period was $0.45 per share. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”. As of December 31, 2014, the Company owed Smith, $854,316 under the terms of his Convertible Note. The Convertible Note was comprised of deferred compensation of $755,468 and accrued interest of $98,848. During January 2015, Smith added previously recorded expenses of $18,582 to his Convertible Note and subsequently converted a total of $106,099 of his Convertible Note into 235,775 Units at $0.45 per unit. Smith also converted $6,280 to purchase 12,561 units of the Company’s unit offering (Note 9). During the year ended June 30, 2014, Bassani elected to convert $110,000 of his Convertible Note, at a conversion price of $0.84, into 130,953 Units consisting of 130,953 shares of the Company’s common stock which were issued during the year ended June 30, 2015 and 130,953 warrants (which were issued during the year ended June 30, 2014). As of December 31, 2014, the Company owed Bassani, $1,188,165, comprised of deferred compensation of $1,034,000 and accrued interest of $154,165, under the terms of his Convertible Note. During February 2015, the Company entered into new 2015 Convertible Notes with effective dates of January 1, 2015, which extended the maturity date of the new notes to December 31, 2017 and revised the terms (see below). 2015 Convertible Notes The 2015 Convertible Notes accrue interest at 4% per annum and are due and payable on December 31, 2017. The 2015 Convertible Notes (including accrued interest, plus all future deferred compensation or other sums subsequently added to the principal of the 2015 Convertible Notes), are convertible, at the sole election of the noteholder, into Units consisting of one share of the Company’s common stock and one quarter warrant to purchase a share of the Company’s common stock, at a price of $0.50 per Unit until December 31, 2020. The warrant contained in the Unit shall be exercisable at $1.00 per share until December 31, 2020. The original conversion price of $0.50 per Unit approximated the fair value of the Units at the date of the agreements; therefore no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”. As of June 30, 2015, Bassani’ s 2015 Convertible Note balance is $1,493,436, which includes the transferred balances of his Convertible Note of $1,188,166, deferred compensation of $239,250 and accrued interest from Loans payable – affiliates of $37,130, plus accrued interest of $28,890 for the year ended June 30, 2015. As of June 30, 2015, Smith’s 2015 Convertible Note balance is $775,520, which includes the transferred balance of his Convertible Note effective January 1, 2015, adjusted for conversions, of $760,518, plus accrued interest of $15,002 for the year ended June 30, 2015. During February 2015, the Company also entered an extension agreement with Schafer, effective January 1, 2015, whereby he was issued a 2015 Convertible Note. The original principal of Schafer’s 2015 Convertible Note is $378,290, comprised of $243,750 previously owed deferred compensation, $14,540 of interest on the deferred compensation and $120,000 of retroactive compensation for calendar year 2014. As of June 30, 2015, the total of Schafer’s 2015 Convertible Note including accrued interest of $7,462, is $385,752.

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	12 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	9 . STOCKHOLDERS' EQUITY: Series B Preferred stock: At July 1, 2014, the Company had 200 shares of Series B redeemable convertible Preferred stock outstanding with a par value of $0.01 per share, convertible at the option of the holder at $2.00 per share, with dividends accrued and payable at 2.5% per quarter. The Series B Preferred stock is mandatorily redeemable at $2.00 per share by the Company three years after issuance and accordingly was classified outside of shareholders’ equity. The 200 shares have reached their maturity date, but due to the cash constraints of the Company have not been redeemed as of September 18, 2015. During the years ended June 30, 2015 and 2014, the Company declared dividends of $2,000 and $2,000 respectively. At June 30, 2015, accrued dividends payable are $8,000. Common stock: Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future. Centerpoint holds 704,309 shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest. The Company accounts for these shares similar to treasury stock. During the year ended June 30, 2014, the Company issued 360,066 shares of the Company’s common stock at prices ranging from $0.75 to $1.85 per share for consulting services valued at $307,102, in the aggregate, to consultants and employees, including 120,000 shares of fully vested bonus shares granted to Mr. Smith in fiscal years 2012 and 2013 which were expensed at grant date. During the year ended June 30, 2014, the Company issued 13,369 shares of the Company’s common stock at prices ranging from $1.46 to $1.51 per share for accounts payable of $19,940. During the year ended June 30, 2014, the Company issued 250,000 shares of the Company’s common stock upon Smith’s and Bassani’s election to convert $187,500 and $110,000, respectively, of their convertible notes payable – affiliate into Units at conversion prices of $0.75 and $0.84 per Unit, respectively (Note 7). During the year ended June 30, 2014, the Company sold 592,534 shares of the Company’s restricted common stock at $0.75 per share for total proceeds of $474,400, net proceeds of $467,575 (including subscriptions receivable of $30,000 for 40,000 shares at June 30, 2014, all of which was received in July 2014). During the year ended June 30, 2014, the Company sold 400,000 shares of the Company’s restricted common stock at $1.25 per share for total net proceeds of $500,000. The subscription agreement for the sale of these shares included a provision whereby the subscription agreement would be modified if the Company issued securities on more favorable terms prior to December 31, 2014. As such the Company issued an additional 266,667 common shares to the subscriber during the year ended June 30, 2014 due to the sale of common stock at $0.75 per share. The Company also issued 20,000 shares of the Company’s restricted common stock upon receipt of its subscription receivable of $25,000 during the year ended June 30, 2014. During the year ended June 30, 2015, the Company issued 45,647 shares of the Company’s common stock at prices ranging from $0.43 to $1.22 per share for services valued at $41,028, in the aggregate, to consultants, a former employee and two employees. The Company also issued 75,000 shares of fully vested bonus shares granted to Mr. Smith in fiscal year 2013 which were expensed at grant date. During the year ended June 30, 2015, the Company issued 130,953 shares of the Company’s common stock upon Bassani’s fiscal year 2014 election to convert $110,000, of his convertible notes payable – affiliate into Units at a conversion price of $0.84 per Unit (Note 8). During the year ended June 30, 2015, the Company sold 35,000 shares of the Company’s restricted common stock at $0.75 per share for total proceeds of $26,250. The Company also issued 40,000 shares of the Company’s restricted common stock upon receipt of its subscription receivable of $30,000 during the year ended June 30, 2015. During the year ended June 30, 2015, the Company entered into subscription agreements to sell units for $0.50 each, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one half of a share of the Company’s restricted common stock for $0.75 per share until December 31, 2016 and pursuant thereto, the Company issued 1,800,000 units for total proceeds of $900,000, which included Smith’s purchase of 12,561 units by converting $6,280 of Convertible Notes . During the year ended June 30, 2015 cash commissions of $61,522 were paid to brokers related to the unit offering in addition to the issuance of 123,044 broker’s warrants to purchase the Company’s common stock at $0.75 per share until June 30, 2016. The broker’s warrants were valued at $0.05 per warrant and $6,152 was recorded to interest expense during the year ended June 30, 2015. The Company allocated the proceeds from the shares and the warrants based upon their relative fair values, using the share price on the day each of the subscription agreements were entered into and the fair value of the warrants, which was determined to be $0.05 per warrant. As a result, $34,826 was allocated to the warrants and $865,174 was allocated to the shares, and both were recorded as additional paid in capital. During the year ended June 30, 2015, the Company entered into subscription agreements to exercise certain warrants with expiry dates on or before December 31, 2015, into restricted shares of the Company’s common stock at a reduced exercise price of $1.05, for the period from May 13, 2015 through June 30, 2015. The Company extended the offering for an additional 15 days to July 15, 2015 and therefore any warrants which would have expired on June 30, 2015 were automatically extended to July 15, 2015. As the $1.05 exercise price was a reduction from the original exercise prices of the warrants, and due to the limited time in which the warrant holders had to subscribe, the reduction in the offering price was accounted for as an inducement and a conversion inducement of $9,593 was recorded. Pursuant to the offering, 71,133 warrants were exercised and 71,133 shares of the Company’s restricted common stock were issued resulting in cash proceeds of $74,690 for the year ended June 30, 2015. The Company had entered into a subscription agreement to exercise 12,500 warrants at $1.05 for which a subscription receivable of $13,125 was recorded at June 30, 2015. During the year ended June 30, 2015, Smith elected to convert $106,099 of his Convertible Notes at $0.45 per unit into 235,775 units of the Company, consisting of one share of the Company’s common stock and one warrant to purchase the Company’s common stock at a price of $1.50 until December 31, 2020. During the year ended June 30, 2015, Smith and various consultants elected to convert $80,780 of deferred compensation into 99,523 shares of the Company’s common stock at conversion rates ranging from $0.72 to $1.24 per share. Warrants: As of June 30, 2015, the Company had approximately 9.5 million warrants outstanding, with exercise prices from $0.75 to $3.10 and expiring on various dates through December 31, 2020. The weighted-average exercise price for the outstanding warrants is $1.44, and the weighted-average remaining contractual life as of June 30, 2015 is 4.1 years. During the year ended June 30, 2014 warrants to purchase 35,465 shares of the Company’s common stock at prices ranging from $1.12 to $1.71 per share were issued pursuant to an agreement with a consultant. The warrants were determined to have a fair value of $0.10 per warrant and expire five years from date of issuance. The Company recorded non-cash compensation expense of $3,546 related to the warrant issuances. The Company entered into an agreement with the consultant whereby the 35,465 warrants issued during the year ended June 30, 2014 and 38,786 warrants previously issued carry an exercise bonus equal to 75% of the exercise price to be offset against the exercise price if exercised after 24 months from the issuance of the warrants. During the year ended June 30, 2014, warrants to purchase 105,000 shares of the Company’s common stock at $0.85 per share were issued pursuant the promissory notes entered into by Bassani and Shareholder (Note 4). The warrants were determined to have a fair value of $0.10 per warrant and expire on December 31, 2018. The Company recorded interest expense of $10,500 related to the warrant issuances. During the year ended June 30, 2014, the Company issued 250,000 warrants to purchase common stock of the Company at $2.50 per share with December 31, 2018 expiry dates, due to Smith’s election to convert $187,500 of his convertible note payable – affiliate into Units at a conversion price of $0.75 per Unit (Note 9). During the year ended June 30, 2014, the Company issued 130,953 warrants to purchase common stock of the Company at $2.50 per share with December 31, 2018 expiry dates, due to Bassani’s election to convert $110,000 of his convertible note payable – affiliate into Units at a conversion price of $0.84 per Unit (Note 8). During the year ended June 30, 2014, warrants to purchase 25,000 shares of common stock of the Company at $2.00 per share expired. During the year ended June 30, 2015, warrants to purchase 67,500 shares of the Company’s common stock at $0.85 per share were issued pursuant the promissory notes entered into by Bassani and Shareholder (Note 4). The warrants were determined to have a fair value of $0.10 per warrant and expire on December 31, 2018. The Company recorded interest expense of $6,750 related to the warrant issuances. During the year ended June 30, 2015, the Company issued warrants to purchase 900,000 shares of the Company’s restricted common stock for $0.75 per share until December 31, 2016 in connection with the sale of 1,800,000 units. The Company also issued 123,044 warrants to purchase shares of the Company’s restricted common stock for $0.75 per share until June 30, 2016 to brokers as commission related to the sale of the units. The warrants were deemed to have a fair value of $0.05 per warrant and the Company recorded interest expense of $6,152 related to the warrant issuances. In conjunction with the execution of Bassani and Smith’s extension agreements (Note 13), 3,906,953 and 1,883,324 warrants issued to Bassani and Smith (and their donees), respectively, were extended until December 31, 2020 and certain warrants with an exercise price in excess of $1.50 were reduced to $1.50. The Company recorded non-cash compensation expense related to the modification of the warrants of $223,589 for the year ended June 30, 2015. During the year ended June 30, 2015, the Company agreed to extend the expiration date of 985,833 warrants owned by various individuals which were scheduled to expire on December 31, 2014 to March 31, 2015. The Company recorded expense related to the modification of the warrants of $986 for the year ended June 30, 2015. During the year ended June 30, 2015, the Company agreed to extend the expiration date of 1,260,833 warrants owned by various individuals which were scheduled to expire between March 31, 2015 and April 30, 2015 to June 30, 2015. The Company recorded interest expense of $6,061 related to the modification of the warrants for the year ended June 30, 2015. During the year ended June 30, 2015, the Company entered into subscription agreements to exercise certain warrants with expiry dates on or before December 31, 2015, into restricted shares of the Company’s common stock at a reduced exercise price of $1.05, for the period from May 13, 2015 through June 30, 2015. The Company extended the offering for an additional 15 days to July 15, 2015 and therefore any warrants which would have expired on June 30, 2015 were automatically extended to July 15, 2015. As a result of the offering, 71,133 warrants were exercised and 71,133 shares of the Company’s restricted common stock were issued resulting in cash proceeds of $74,690 for the year ended June 30, 2015. Stock options: The Company’s 2006 Consolidated Incentive Plan (the “2006 Plan”), as amended effective February 1, 2015, provides for the issuance of options to purchase up to 22,000,000 shares of the Company’s common stock. Terms of exercise and expiration of options granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. In July 2013, the Company entered into an agreement with a terminated employee which entitled the former employee to modifications of existing stock options resulting in the extension of certain expiration dates and resulting in incremental non-cash compensation expense of $97,125 for the year ended June 30, 2014. During the year ended June 30, 2014, the Company entered into agreements with Schafer and a board member, pursuant to which each is entitled to execution/exercise bonuses identical to those previously offered to Bassani and Smith (Note 13). The modification of the options for Schafer and the board member resulted in incremental non-cash compensation expense of $210,513 for the year ended June 30, 2014. In November 2014, the Company entered into an agreement with a board member which entitled the board member to modifications of existing stock options resulting in the extension of certain expiration dates and resulting in incremental non-cash compensation expense of $11,783 for the year ended June 30, 2015. In February 2015, the Company entered into extension agreements with Bassani, Smith and Schafer (Note 13) which entitled them to modifications of existing stock options resulting in the extension of certain expiration dates and the reduction of certain exercise prices. The option modifications resulted in incremental non-cash compensation expense of $357,500 for the year ended June 30, 2015. The Company recorded compensation expense/(credits) related to employee stock options of $501,609 and $(204,257) for the years ended June 30, 2015 and 2014, respectively. The Company granted 957,500 and 97,725 options during the years ended June 30, 2015 and 2014, respectively. During the year ended June 30, 2015, 802,500 options expired, while during the year ended June 30, 2014, 200,000 options were forfeited and 900,000 options expired . The fair value of the options granted during the years ended June 30, 2015 and 2014 were estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions: Weighted average, June 30, 2015 Range, June 30, 2015 Weighted average, June 30, 2014 Range, June 30, 2014 Volatility 76% 74% - 80% 54% 49% - 65% Dividend yield - - - - Risk-free interest rate 1.55% 0.51% - 1.79% 0.95% 0.59% - 1.69% Expected term (years) 6.1 2 - 10 3.29 2.63 - 4.67 The expected volatility was based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates. A summary of option activity under the 2006 Plan for the two years ended June 30, 2015 is as follows: Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at July 1, 2013 5,261,145 $ 2.84 4.0 - Granted 97,725 1.35 Exercised - - Forfeited (200,000 ) 3.00 Expired (900,000 ) 2.84 Outstanding at June 30, 2014 4,258,870 2.81 3.2 - Granted 957,500 0.74 Exercised - - Forfeited - - Expired (802,500 ) 2.7 Outstanding at June 30, 2015 4,413,870 $ 1.88 4.3 $ 398,250 Exercisable at June 30, 2015 4,313,870 $ 1.91 4.2 $ 344,250 The following table presents information relating to nonvested stock options as of June 30, 2015: Options Weighted Average Grant-Date Fair Value Nonvested at July 1, 2014 - $ - Granted 957,500 0.58 Vested (857,500 ) (0.56 ) Nonvested at June 30, 2015 100,000 $ 0.76 The total fair value of stock options that vested during the years ended June 30, 2015 and 2014 was $476,075 and $54,022, respectively. As of June 30, 2015, the Company had $50,466 of unrecognized compensation cost related to stock options. Stock-based employee compensation charges in operating expenses in the Company’s financial statements for the years ended June 30, 2015 and 2014 are as follows: Year ended June 30, 2015 Year ended June 30, 2014 General and administrative: Fair value of stock options expensed/(credited) $ 378,937 $ (87,517 ) Fair value of stock issued to an employee - 94,998 Change in fair value from modification of option terms 369,283 307,638 Change in fair value from modification of warrant terms 223,917 - Total $ 972,137 $ 315,119 Research and development: Fair value of stock options expensed/(credited) $ 122,672 $ (116,739 ) Total $ 122,672 $ (116,739 )

Note 10 - Gain on Extinguishmen

Note 10 - Gain on Extinguishment of Liabilities	12 Months Ended
	Jun. 30, 2015
Gain On Extinguishment Of Liabilities [Abstract]
Gain On Extinguishment Of Liabilities [Text Block]	10 . GAIN ON EXTINGUISHMENT OF LIABILITIES: During the year ended June 30, 2014, the Company recognized other income due to the extinguishment of liabilities of $20,113, resulting from the legal release of certain accounts payable. These accounts payable, which related to business activities of the Company discontinued during the 2008 fiscal year, were outstanding for 5-6 years and the vendor had made no attempt to collect these amounts from the Company over the past several years. The extinguishment of liabilities was recorded after a review of the statute of limitations in the state in which the original liability was incurred.

Note 11 - Income Taxes

Note 11 - Income Taxes	12 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	11 . INCOME TAXES: The reconciliation between the expected federal income tax benefit computed by applying the Federal statutory rate to loss before income taxes and the actual benefit for taxes on loss for the years ended June 30, 2015 and 2014 is as follows: 2015 2014 Expected income tax benefit at statutory rate $ (1,918,000 ) $ (1,959,000 ) State taxes, net of federal benefit (173,000 ) (177,000 ) Permanent differences and other (19,000 ) (19,000 ) Change in valuation allowance 2,110,000 2,155,000 Income tax benefit $ - $ - The Company has net operating loss carry-forwards (“NOLs”) for tax purposes of approximately $50,194,000 as of June 30, 2015. These NOLs expire on various dates through 2035. The utilization of the NOLs may be limited under Section 382 of the Internal Revenue Code. The Company’s deferred tax assets for the years ended June 30, 2015 and 2014 are estimated as follows: 2015 2014 NOLs – noncurrent $ 19,083,000 $ 18,392,000 Stock-based compensation - current 5,255,000 4,832,000 Property and equipment – noncurrent 1,390,000 741,000 Deferred compensation - noncurrent 1,383,000 1,036,000 27,111,000 25,001,000 Valuation allowance (27,111,000 ) (25,001,000 ) Net deferred tax assets $ - $ - The Company has provided a valuation allowance of 100% of its net deferred tax asset due to the uncertainty of generating future profits that would allow for the realization of such deferred tax assets.

Note 12 - 401(k) Plan

Note 12 - 401(k) Plan	12 Months Ended
	Jun. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	1 2 . 401(k) PLAN: The Company has adopted the Bion Technologies, Inc. 401(k) Profit Sharing Plan and Trust (the “401(k) Plan”), a defined contribution retirement plan for the benefit of its employees. The 401(k) Plan is currently a salary deferral only plan and at this time the Company does not match employee contributions. The 401(k) is open to all employees over 21 years of age and no service requirement is necessary.

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	12 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	1 3 . COMMITMENTS AND CONTINGENCIES: Employment and consulting agreements: Smith has held the positions of Director, President and General Counsel of Company and its subsidiaries under various agreements and terms since March 2003. During July 2011, the Company entered into an extension agreement pursuant to which Smith continued to hold his current position in the Company through a date no later than December 31, 2012. Commencing January 1, 2012, Smith’s monthly salary was $20,000, which has been accrued and deferred. In addition, 90,000 shares of the Company’s common stock would be issued to Smith in two tranches of 45,000 shares on each of January 15, 2013 (issued) and 2014 (issued), respectively. The Company recorded expense of $240,300 for the year ended June 30, 2012, related to the future stock issuances as the bonus was fully vested at the grant date. Effective July 15, 2012, the Company entered into an extension agreement pursuant to which Smith will continue to hold his current positions in the Company through a date no later than June 30, 2014. Effective September 2012, Smith’s monthly salary became $21,000, until March 2014, at which time Smith agreed to a temporary reduction in monthly salary to $14,000 (which has been deferred). In addition, the extension provides that Smith will be issued 150,000 shares of the Company’s common stock in two tranches of 75,000 shares on each of January 15, 2014 (issued) and 2015 (issued), which shares vested immediately. The Company recorded expense of $292,500 for the year ended June 30, 2013, related to the future stock issuances as the bonus was fully vested at the grant date. As part of the extension agreement, Smith was also granted a bonus of $25,000 paid in warrants, which vested immediately, to purchase 250,000 shares of the Company’s common stock at a price of $2.10 per share and which warrants expire on December 31, 2018 and a contingent stock bonus of 100,000 shares payable on the date on which the Company’s stock price first reaches $10.00 per share (regardless of whether Smith is still providing services to the Company on such date). During September 2014, Smith agreed to continue his employment agreement through April 15, 2015 and also agreed to continue to defer his temporarily reduced salary of $14,000 per month until such date. On February 10, 2015, the Company executed an Extension Agreement with Smith pursuant to which Smith extended his employment with the Company to December 31, 2015 (with the Company having an option to extend his employment an additional six months). As part of the Extension Agreement, the balance of Smith’s existing convertible note payable (Note 8) of $854,316 as of December 31, 2014, adjusted for conversions subsequent to that date, was replaced with a new convertible note with an initial principal amount of $760,520 with terms that i) materially reduce the interest rate by 50% (from 8% to 4%), ii) increases the conversion price by 11% (from $0.45 to $0.50), iii) sets the conversion price at a fixed price so there can be no further reductions, iv) reduces the number of warrants received on conversion by 75% (from 1 warrant per unit to ¼ per unit) and v) extends the maturity date to December 31, 2017. Additionally, pursuant to the Extension Agreement, Smith: i) will continue to defer his cash compensation ($18,000 per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation, ii) cancelled 150,000 contingent stock bonuses previously granted to him by the Company, iii) has been granted 150,000 new options which vested immediately and iv) outstanding options and warrants owned by Smith (and his donees) have been extended and had the exercise prices reduced to $1.50. Since March 31, 2005, the Company has had various agreements with Brightcap and/or Bassani, through which the services of Bassani are provided. The Board appointed Bassani as the Company's CEO effective May 13, 2011. On July 15, 2011, Bassani, Brightcap and the Company agreed to an extension/amendment of the existing agreement with Brightcap which provided that Bassani would continue to provide the services of CEO through June 30, 2013 and will continue to provide full-time services to the Company in other capacities through June 30, 2014 at a salary of $26,000 per month. In addition Bassani will be issued 300,000 shares of the Company’s common stock issuable in three tranches of 100,000 shares on each of January 15, 2015, 2016 and 2017, respectively. During the year ended June 30, 2012 the Company recorded expense of $795,000 related to the future stock issuances as the bonus was fully vested at the grant date. Effective July 15, 2012, Bassani, Brightcap and the Company agreed to a further extension/amendment of the existing agreement with Brightcap which provides that Bassani will continue to provide the services of CEO through June 30, 2014. The extension provided that Bassani will continue to provide full-time services to the Company at a cash salary of $26,000 per month (which was deferred) and Bassani will be issued 300,000 shares of the Company’s common stock issuable in two tranches of 150,000 shares on each of January 15, 2015 and 2016, respectively, which were immediately vested. The Company recorded expense of $585,000 for the year ended June 30, 2013, related to the future stock issuances as the bonus was fully vested at the grant date. During September 2014, Bassani agreed to extend his employment agreement until April 15, 2015 and that previously issued and expensed share grants of 100,000 and 150,000 shares that were to be issued on January 15, 2015, would be deferred until January 15, 2016. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017, (with the Company having an option to extend the term an additional six months.) As part of the agreement, the Company’s existing loan payable, deferred compensation and convertible note payable to Bassani (Notes 4, 6 and 8), were restructured into two promissory notes as follows: a) The of sum of the cash loaned by Bassani to the Company of $279,000 together with $116,277 of unreimbursed expenses through December 31, 2014 were placed into a new promissory note with initial principal of $395,277 which is due and payable on December 31, 2015 (Note 5). In connection with these sums and the new promissory note, Bassani was issued warrants to purchase 592,916 shares of the Company’s common stock at a price of $1.00 until December 31, 2020; and b) the remaining balances of the Company’s accrued obligations to Bassani ($1,464,545) were replaced with a new convertible promissory note with terms that compared with the largest prior convertible note obligation to Bassani: i) materially reduce the interest rate by 50% (from 8% to 4%), ii) increase the conversion price by 11% (from $0.45 to $0.50), iii) sets the conversion price at a fixed price so there can be no further reductions, iv) reduces the number of warrants received on conversion by 75% (from 1 warrant per unit to 1/4 per unit) and v) extends the maturity date to December 31, 2017 (Note 8). Additionally, pursuant to the Extension Agreement, Bassani i) will continue to defer his cash compensation ($31,000 per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation, ii) cancelled 250,000 contingent stock bonuses previously granted to him by the Company, iii) has been granted 450,000 new options which vested immediately and iv) outstanding options and warrants owned by Bassani (and his donees) have been extended and had the exercise prices reduced to $1.50 (if the exercise price exceeded $1.50). On February 10, 2015, the Company entered into an agreement with Schafer pursuant to which Schafer will continue to provide services to the Company through December 31, 2015. As part of the agreement, unreimbursed expenses of $15,956 due to Schafer at December 31, 2014 were replaced with a new promissory note with initial principal of $15,956 which is due and payable on December 31, 2015 and Schafer was issued warrants to purchase 7,978 shares of the Company’s common stock at a price of $1.00 until December 31, 2020 (Note 5). Schafer’s deferred compensation for 2014 (and prior years) in the amount of $394,246 (including a sum of $120,000 for calendar year 2014) was placed in a convertible promissory note (Note 8). Additionally, pursuant to the agreement, i) the exercise period of outstanding options and warrants owned by Schafer have been extended, and ii) 25,000 contingent stock bonuses previously granted to Schafer have been cancelled by the Company. Contingent stock bonuses: The Company has declared contingent deferred stock bonuses to its key employees and consultants at various times throughout the years. The stock bonuses are contingent upon the Company’s stock price exceeding a certain target price per share, and the grantees still being employed by or providing services to the Company at the time the target prices are reached. The Company’s outstanding contingent stock bonuses as of June 30, 2015 are as follows: Target Price per share $ 5.00 $ 10.00 $ 20.00 Number of shares 50,000 40,000 27,500 Execution/exercise bonuses: As part of the agreements the Company entered into with Bassani and Smith (Note 13) effective May 15, 2013, whereby they agreed to continue to defer their cash compensation up to April 30, 2014, they were each granted the following: a) a 50% execution/exercise bonus which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the bonus shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock bonuses, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. During the year ended June 30, 2014, the Company extended execution/exercise bonuses with the same terms as described above to Schafer and to Jon Northrup, the Company’s other board member. As of June 30, 2015, the execution/exercise bonus was applicable to 2,945,000 of the Company’s outstanding options and 6,759,500 of the Company’s outstanding warrants. Litigation: In May 2014 Mr. Morris, the Company’s former Chief Technology Officer, initiated litigation against the Company (Morris v Bion Environmental Technologies, Inc., 14-cv-02732-ADS-GRB, United States District Court, Eastern District of New York) related to his termination effective November 30, 2013. Mr. Morris sought payment of severance pay (up to $90,000) plus certain previously accrued obligations totaling approximately $87,000 plus accrued interest (which sums had been accrued as of December 31, 2014, despite the fact that the Company was disputing the obligations) and attorney’s fees. The Company and Mr. Morris entered into a negotiated general release and waiver of all claims in March 2015, whereby the Company agreed to pay Mr. Morris and his attorney $20,000 and $10,000, respectively and issued Mr. Morris 10,000 shares of the Company’s common stock valued at $6,600. On April 9, 2015, the case was formally closed by the presiding judge. As a result of the general release, during the year ended June 30, 2015, the Company reversed approximately $271,000 of previously recorded expenses for deferred compensation and severance pay which it had accrued in relation to Mr. Morris’ employment with and termination by the Company. On September 25, 2014, Pennvest exercised its right to declare the Pennvest Loan in default and has accelerated the Pennvest Loan and has demanded that PA-1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA-1 did not make the payment and does not have the resources to make the payment demanded by Pennvest. During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan is now solely an obligation of PA-1. No litigation has commenced related to this matter but such litigation is likely if negotiations do not produce a resolution (Note 1 and Note 7). The Company currently is not involved in any other material litigation.

Note 14 - Subsequent Events

Note 14 - Subsequent Events	12 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	1 4 . SUBSEQUENT EVENTS: The Company has evaluated events that occurred subsequent to June 30, 2015 for recognition and disclosure in the financial statements and notes to the financial statements. From July 1, 2015 through September 21, 2014 the Company has issued 29,934 shares of the Company’s common shares to an employee and consultants valued at approximately $26,000. From July 1, 2015 through September 21, 2015, the Company entered into subscription agreements to exercise certain warrants with expiry dates on or before December 31, 2015, into restricted shares of the Company’s common stock at a reduced exercise price of $1.05. As a result of the offering, 278,394 warrants were exercised and 278,394 shares of the Company’s restricted common stock were issued resulting in cash proceeds of approximately $187,300 and a collateralized promissory note for $105,000. The promissory note bears interest at 4% per annum and is payable in full on January 31, 2016. From July 1, 2015 through September 21, 2015, consultants elected to convert approximately $88,800 of deferred compensation into 109,715 shares of the Company’s common shares. From July 1, 2015 through September 21, 2015, Smith elected to convert approximately $82,900 of his deferred compensation into 99,159 shares of the Company’s common shares. As of September 18, 2015 Smith’s current deferred compensation balance is nil. Effective September 8, 2015, the Company entered into convertible promissory notes with Bassani, Shafer and Shareholder which replace existing notes payable – affiliates (Note 5). The initial principal balances of such notes are $405,831, $16,382 and $82,921, respectively. The new convertible promissory notes bear interest at 4% per annum, have maturity dates of December 31, 2017 and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.60 per share.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of consolidation: The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc. (“Projects Group”), Bion Technologies, Inc., BionSoil, Inc., Bion Services, PA-1, and Bion PA 2 LLC; and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash: The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment: Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.
Derivatives, Policy [Policy Text Block]	Derivative Financial Instruments: Pursuant to Accounting Standards Codification (“ASC”) Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative assets or liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.
Equity Issuances, Warrants, Policy [PolicyText Block]	Warrants: The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of credit risk: The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.
Minority Interest, Policy [Policy Text Block]	Noncontrolling interests: In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.
Fair Value Measurement, Policy [Policy Text Block]	Fair value measurements: Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value. Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 – assets and liabilities whose significant value drivers are unobservable. Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable approximates its carrying amount as it bears interest at rates commensurate with market rates. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of deferred compensation, notes payable - affiliates and loans payable – affiliates are not practicable to estimate due to the related party nature of the underlying transactions.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition: Revenues are generated from the sale of nutrient reduction credits. The Company recognizes revenue from the sale of nutrient credits when there is persuasive evidence that an arrangement exists, when title has passed, the price is fixed or determinable, and collection is reasonably assured. The Company expects that technology license fees will be generated from the licensing of Bion’s integrated system. The Company anticipates that it will charge its customers a non-refundable up-front technology license fee, which will be recognized over the estimated life of the customer relationship. In addition, any on-going technology license fees will be recognized as earned based upon the performance requirements of the agreement. Annual waste treatment fees will be recognized upon receipt. Revenues, if any, from the Company’s interest in Integrated Projects will be recognized when the entity in which the Integrated Project has been developed recognizes such revenue.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-based compensation: The Company recognizes the cost of employee services received in exchange for an award of equity instruments in the financial statements and the cost is measured based on the grant date fair value of the award. The stock option compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (the requisite service period). The Company utilizes the Black-Scholes option-pricing model to determine fair value. Key assumptions of the Black-Scholes option-pricing model include applicable volatility rates, risk-free interest rates and the instrument’s expected remaining life. These assumptions require significant management judgment. The Company has issued non-employee options that include service conditions and have graded vesting schedules. Generally for these arrangements, the measurement date of the services occurs when the options vest. Recognition of compensation cost for reporting periods prior to the measurement date is based on the then current fair value of the options. Fair value of the options is determined using a Black-Scholes option-pricing model. Any subsequent changes in fair value will be recorded on the measurement date. Compensation cost in connection with options that are not fully vested is being recognized on a straight-line basis over the requisite service period for the entire award.
Income Tax, Policy [Policy Text Block]	Income taxes: The Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their tax bases, as well as net operating losses. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets or liabilities of a change in tax rates is recognized in the period in which the tax change occurs. A valuation allowance is provided to reduce the deferred tax assets by 100%, since the Company believes that at this time it is more likely than not that the deferred tax asset will not be realized. The Company is no longer subject to U.S. federal and state tax examinations for fiscal years before 2009. Management does not believe there will be any material changes in the Company’s unrecognized tax positions over the next 12 months. The Company's policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. As of June 30, 2015, there were no penalties or accrued interest amounts associated with any unrecognized tax benefits, nor was any interest expense recognized during the years ended June 30, 2015 and 2014.
Earnings Per Share, Policy [Policy Text Block]	Loss per share: Basic loss per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted loss per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the loss per share. During the years ended June 30, 2015 and 2014, the basic and diluted loss per share was the same, as the impact of potential dilutive common shares was anti-dilutive. The following table represents the warrants, options and convertible securities excluded from the calculation of diluted loss per share: June 30, 2015 June 30, 2014 Warrants 9,532,189 7,622,653 Options 4,413,870 4,258,870 Convertible debt 6,056,270 2,820,157 Convertible preferred stock 14,000 13,000 The following is a reconciliation of the denominators of the basic loss per share computations for the years ended June 30, 2015 and 2014: Year ended June 30, 2015 Year ended June 30, 2014 Shares issued – beginning of period 19,576,619 17,673,983 Shares held by subsidiaries (Note 9) (704,309 ) (704,309 ) Shares outstanding – beginning of period 18,872,310 16,969,674 Weighted average shares for fully vested stock bonuses (Note 9) 675,000 840,000 Weighted average shares issued during the period 998,146 826,690 Basic weighted average shares – end of period 20,545,456 18,636,364
Reclassification, Policy [Policy Text Block]	Reclassifications: Certain amounts in the prior year financial statements have been reclassified to conform to the current year presentation.
Use of Estimates, Policy [Policy Text Block]	Use of estimates: In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements: The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company’s financial statements properly reflect the change. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09 “Revenue from Contracts from Customers,” which supersedes the revenue recognition requirements in “Revenue Recognition (Topic 605),” and requires entities to recognize revenue in a way that depicts the transfer of potential goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to the exchange for those goods or services. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017 and early adoption is not permitted. The Company is currently evaluating the new standard and assessing the potential impact on its operations and financial statements. In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements – Going Concern: Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. The guidance is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early application is permitted. The Company believes that the adoption of ASU No. 2014-15 will not have a material impact on its financial statements.

Note 2 - Significant Accounti21

Note 2 - Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	June 30, 2015 June 30, 2014 Warrants 9,532,189 7,622,653 Options 4,413,870 4,258,870 Convertible debt 6,056,270 2,820,157 Convertible preferred stock 14,000 13,000
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year ended June 30, 2015 Year ended June 30, 2014 Shares issued – beginning of period 19,576,619 17,673,983 Shares held by subsidiaries (Note 9) (704,309 ) (704,309 ) Shares outstanding – beginning of period 18,872,310 16,969,674 Weighted average shares for fully vested stock bonuses (Note 9) 675,000 840,000 Weighted average shares issued during the period 998,146 826,690 Basic weighted average shares – end of period 20,545,456 18,636,364

Note 3 - Property and Equipme22

Note 3 - Property and Equipment (Tables)	12 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	June 30, 2015 June 30, 2014 Machinery and equipment $ 2,923,577 $ 4,111,001 Buildings and structures 1,385,125 1,947,701 Computers and office equipment 175,248 183,809 4,483,950 6,242,511 Less accumulated depreciation (2,506,731 ) (1,891,358 ) $ 1,977,219 $ 4,351,153

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Tables)	12 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Weighted average, June 30, 2015 Range, June 30, 2015 Weighted average, June 30, 2014 Range, June 30, 2014 Volatility 76% 74% - 80% 54% 49% - 65% Dividend yield - - - - Risk-free interest rate 1.55% 0.51% - 1.79% 0.95% 0.59% - 1.69% Expected term (years) 6.1 2 - 10 3.29 2.63 - 4.67
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at July 1, 2013 5,261,145 $ 2.84 4.0 - Granted 97,725 1.35 Exercised - - Forfeited (200,000 ) 3.00 Expired (900,000 ) 2.84 Outstanding at June 30, 2014 4,258,870 2.81 3.2 - Granted 957,500 0.74 Exercised - - Forfeited - - Expired (802,500 ) 2.7 Outstanding at June 30, 2015 4,413,870 $ 1.88 4.3 $ 398,250 Exercisable at June 30, 2015 4,313,870 $ 1.91 4.2 $ 344,250
Schedule of Nonvested Share Activity [Table Text Block]	Options Weighted Average Grant-Date Fair Value Nonvested at July 1, 2014 - $ - Granted 957,500 0.58 Vested (857,500 ) (0.56 ) Nonvested at June 30, 2015 100,000 $ 0.76
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Year ended June 30, 2015 Year ended June 30, 2014 General and administrative: Fair value of stock options expensed/(credited) $ 378,937 $ (87,517 ) Fair value of stock issued to an employee - 94,998 Change in fair value from modification of option terms 369,283 307,638 Change in fair value from modification of warrant terms 223,917 - Total $ 972,137 $ 315,119 Research and development: Fair value of stock options expensed/(credited) $ 122,672 $ (116,739 ) Total $ 122,672 $ (116,739 )

Note 11 - Income Taxes (Tables)

Note 11 - Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2015 2014 Expected income tax benefit at statutory rate $ (1,918,000 ) $ (1,959,000 ) State taxes, net of federal benefit (173,000 ) (177,000 ) Permanent differences and other (19,000 ) (19,000 ) Change in valuation allowance 2,110,000 2,155,000 Income tax benefit $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2015 2014 NOLs – noncurrent $ 19,083,000 $ 18,392,000 Stock-based compensation - current 5,255,000 4,832,000 Property and equipment – noncurrent 1,390,000 741,000 Deferred compensation - noncurrent 1,383,000 1,036,000 27,111,000 25,001,000 Valuation allowance (27,111,000 ) (25,001,000 ) Net deferred tax assets $ - $ -

Note 13 - Commitments and Con25

Note 13 - Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Shares Outstanding under Contingent Stock Bonuses Plan, by Target Price Per Share [Table Text Block]	Target Price per share $ 5.00 $ 10.00 $ 20.00 Number of shares 50,000 40,000 27,500

Note 1 - Organization, Nature26

Note 1 - Organization, Nature of Business, Going Concern and Management's Plans (Details) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Sep. 25, 2014
Note 1 - Organization, Nature of Business, Going Concern and Management's Plans (Details) [Line Items]
Construction Loan	$ 7,800,000
Impairment of Long-Lived Assets Held-for-use	1,750,000	$ 2,000,000
Property, Plant and Equipment, Gross	4,483,950	6,242,511
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	(5,639,588)	(5,761,989)
Working Capital	(10,066,064)
Stockholders' Equity Attributable to Parent	(10,806,933)	(7,530,837)
Proceeds from Issuance or Sale of Equity	1,000,940	$ 944,400
PA-1 [Member]
Note 1 - Organization, Nature of Business, Going Concern and Management's Plans (Details) [Line Items]
Debt Instrument, Debt Default, Amount			$ 8,137,117
Property, Plant And Equipment of PA-1 [Member]
Note 1 - Organization, Nature of Business, Going Concern and Management's Plans (Details) [Line Items]
Impairment of Long-Lived Assets Held-for-use	1,750,000
Property, Plant and Equipment, Gross	1,976,621
Minimum [Member] | Scenario, Forecast [Member]
Note 1 - Organization, Nature of Business, Going Concern and Management's Plans (Details) [Line Items]
Capital Required for Capital Adequacy	2,500,000
Maximum [Member] | Scenario, Forecast [Member]
Note 1 - Organization, Nature of Business, Going Concern and Management's Plans (Details) [Line Items]
Capital Required for Capital Adequacy	$ 50,000,000

Note 2 - Significant Accounti27

Note 2 - Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Note 2 - Significant Accounting Policies (Details) [Line Items]
Deferred Tax Assets Reduction Percentage	100.00%
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	$ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	$ 0	$ 0
Centerpoint [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Equity Method Investment, Ownership Percentage	58.90%
Minimum [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Note 2 - Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	20 years

Note 2 - Significant Accounti28

Note 2 - Significant Accounting Policies (Details) - Antidilutive Securities - shares	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	9,532,189	7,622,653
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	4,413,870	4,258,870
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	6,056,270	2,820,157
Convertible Preferred Stock, Antidilutive Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	14,000	13,000

Note 2 - Significant Accounti29

Note 2 - Significant Accounting Policies (Details) - Earnings Per Share, Basic and Diluted - shares	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Earnings Per Share, Basic and Diluted [Abstract]
Shares issued – beginning of period	19,576,619	17,673,983
Shares held by subsidiaries (Note 9)	(704,309)	(704,309)
Shares outstanding – beginning of period	18,872,310	16,969,674
Weighted average shares for fully vested stock bonuses (Note 9)	675,000	840,000
Weighted average shares issued during the period	998,146	826,690
Basic weighted average shares – end of period	20,545,456	18,636,364

Note 3 - Property and Equipme30

Note 3 - Property and Equipment (Details) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment [Abstract]
Impairment of Long-Lived Assets Held-for-use	$ 1,750,000	$ 2,000,000
Depreciation	$ 623,934	$ 978,798

Note 3 - Property and Equipme31

Note 3 - Property and Equipment (Details) - Property and Equipment - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Property and Equipment [Abstract]
Machinery and equipment	$ 2,923,577	$ 4,111,001
Buildings and structures	1,385,125	1,947,701
Computers and office equipment	175,248	183,809
	4,483,950	6,242,511
Less accumulated depreciation	(2,506,731)	(1,891,358)
	$ 1,977,219	$ 4,351,153

Note 4 - Loans Payable - Affi32

Note 4 - Loans Payable - Affiliates (Details) - USD ($)	2 Months Ended	12 Months Ended
	Mar. 31, 2015	Jun. 30, 2015	Jun. 30, 2014
Note 4 - Loans Payable - Affiliates (Details) [Line Items]
Interest Expense, Related Party		$ 9,840
Accretion Expense		29,608
2015 Promissory Notes [Member]
Note 4 - Loans Payable - Affiliates (Details) [Line Items]
Notes Payable, Related Parties		472,230
Related Party Transaction, Rate	4.00%
Chief Executive Officer [Member]
Note 4 - Loans Payable - Affiliates (Details) [Line Items]
Notes Payable, Related Parties		$ 316,131
Related Party Transaction, Rate		8.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 1.50	$ 2.50
Chief Executive Officer [Member] | 2015 Promissory Notes [Member]
Note 4 - Loans Payable - Affiliates (Details) [Line Items]
Notes Payable, Related Parties	$ 395,277
Class of Warrant or Right, Issued During Period (in Shares)	654,350
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1
Class of Warrant or Right, Issued During Period, Per Dollar of Principal (in Shares)	1.5
Debt Instrument, Unamortized Discount	$ 53,342
Majority Shareholder [Member]
Note 4 - Loans Payable - Affiliates (Details) [Line Items]
Notes Payable, Related Parties		$ 80,764
Related Party Transaction, Rate		8.00%
CEO and Shareholder [Member]
Note 4 - Loans Payable - Affiliates (Details) [Line Items]
Interest Expense, Related Party		$ 14,436	$ 22,433
CEO and Shareholder [Member] | Warrant Loans [Member]
Note 4 - Loans Payable - Affiliates (Details) [Line Items]
Notes Payable, Related Parties			$ 135,000
Class of Warrant or Right, Issued During Period (in Shares)		67,500	33,750
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 0.85	$ 0.85
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)		67,500
Interest Expense, Related Party		$ 6,750
Executive Vice Chairman [Member]
Note 4 - Loans Payable - Affiliates (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 1
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)		7,978
Executive Vice Chairman [Member] | 2015 Promissory Notes [Member]
Note 4 - Loans Payable - Affiliates (Details) [Line Items]
Notes Payable, Related Parties	$ 15,956
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1
Class of Warrant or Right, Issued During Period, Per Dollar of Principal (in Shares)	1.5
Debt Instrument, Unamortized Discount	$ 2,153
Investor [Member] | 2015 Promissory Notes [Member]
Note 4 - Loans Payable - Affiliates (Details) [Line Items]
Notes Payable, Related Parties	$ 80,764
Class of Warrant or Right, Issued During Period (in Shares)	0.5
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 0.10
Debt Instrument, Unamortized Discount	$ 3,720

Note 6 - Deferred Compensation

Note 6 - Deferred Compensation (Details) - USD ($)	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014
Note 6 - Deferred Compensation (Details) [Line Items]
Deferred Compensation Liability, Current	$ 839,288		$ 716,734
Interest Rate on Deferred Compensation	4.00%
Deferred Compensation, Conversion Days	5 days
Deferred Compensation, Consecutive Trading Days	10 days
Chief Executive Officer [Member]
Note 6 - Deferred Compensation (Details) [Line Items]
Deferred Compensation Liability, Current	$ 187,542
Interest Rate on Deferred Compensation		10.00%
Deferred Compensation Arrangement with Individual, Recorded Liability		$ 239,250
Accrued Interest on Deferred Compensation		$ 74,250
Debt Instrument, Convertible, Conversion Price (in Dollars per share)		$ 1.50
Chief Financial Officer [Member]
Note 6 - Deferred Compensation (Details) [Line Items]
Deferred Compensation Liability, Current	64,861
Executive Vice Chairman [Member]
Note 6 - Deferred Compensation (Details) [Line Items]
Deferred Compensation Liability, Current	90,746	$ 243,750
Consultants [Member]
Note 6 - Deferred Compensation (Details) [Line Items]
Deferred Compensation Liability, Current	$ 254,655
Interest Rate on Deferred Compensation	3.00%
Former Employee 1 [Member]
Note 6 - Deferred Compensation (Details) [Line Items]
Deferred Compensation Liability, Current	$ 168,000
Individual Employee [Member]
Note 6 - Deferred Compensation (Details) [Line Items]
Deferred Compensation Liability, Current	$ 984
Deferred Compensation, Shares Issued upon Conversion (in Shares)	226,168
Former Employee [Member]
Note 6 - Deferred Compensation (Details) [Line Items]
Deferred Compensation, Shares Issued upon Conversion (in Shares)	856
Former Employee 2 [Member]
Note 6 - Deferred Compensation (Details) [Line Items]
Deferred Compensation Liability, Current	$ 72,500

Note 7 - Loan Payable (Details)

Note 7 - Loan Payable (Details) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013	Sep. 25, 2014
Note 7 - Loan Payable (Details) [Line Items]
Construction Loan	$ 7,800,000
PA-1 [Member]
Note 7 - Loan Payable (Details) [Line Items]
Debt Instrument, Debt Default, Amount				$ 8,137,117
Pennvest Loan [Member]
Note 7 - Loan Payable (Details) [Line Items]
Construction Loan	7,754,000
Line of Credit Facility, Maximum Borrowing Capacity	7,754,000
Repayments of Long-term Debt		$ 704,000	$ 574,000
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months	723,000
Long-term Debt, Maturities, Repayments of Principal in Year Two	741,000
Long-term Debt, Maturities, Repayments of Principal in Year Three	760,000
Long-term Debt, Maturities, Repayments of Principal in Year Four	4,252,000
Interest Expense, Debt	197,494	$ 197,494
Debt Instrument, Accrued Interest and Late Charges	$ 577,001
Pennvest Loan [Member] | Interest Only Payments, Number of Years [Member]
Note 7 - Loan Payable (Details) [Line Items]
Term Loan Payment Term	3 years
Pennvest Loan [Member] | Years 1 through 5 [Member]
Note 7 - Loan Payable (Details) [Line Items]
Debt Instrument, Interest Rate During Period	2.547%
Pennvest Loan [Member] | Years 6 through Maturity [Member]
Note 7 - Loan Payable (Details) [Line Items]
Debt Instrument, Interest Rate During Period	3.184%

Note 8 - Convertible Notes Pa35

Note 8 - Convertible Notes Payable - Affiliates (Details)	1 Months Ended	12 Months Ended
	Jan. 31, 2015USD ($)$ / sharesshares	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2014USD ($)$ / sharesshares	Mar. 31, 2015$ / shares	Dec. 31, 2014USD ($)$ / shares
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Convertible Notes Payable, Current			$ 1,736,502
Debt Instrument, Convertible, Beneficial Conversion Feature		$ 0
Sale of Units, Value		$ 900,000
Subscription Agreement [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Number of Shares Per Unit		1
Number of Warrants Per Unit		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares		$ 0.75
Sale of Units, Value		$ 900,000
Sale of Units Number of Units Issued (in Shares) | shares		1,800,000
Convertible Notes Payable [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Debt Instrument, Interest Rate, Effective Percentage					8.00%
President [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Convertible Notes Payable, Current					$ 854,316
Number of Shares Per Unit		1
Number of Warrants Per Unit		1
Conversion Price Per Unit (in Dollars per share) | $ / shares		$ 0.45	$ 0.75
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares		$ 1.50	2.50	$ 1.50
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares	$ 0.45		$ 0.75
Deferred Compensation Arrangement with Individual, Compensation Expense	$ 18,582
Debt Conversion, Original Debt, Amount	$ 106,099	$ 106,099	$ 187,500
Debt Conversion, Converted Instrument, Units Issued (in Shares) | shares	235,775	235,775
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | shares			250,000
Convertible Notes Payable					854,316
President [Member] | Subscription Agreement [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Sale of Units, Value	$ 6,280	$ 6,280
Sale of Units Number of Units Issued (in Shares) | shares	12,561	12,561
Chief Executive Officer [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Convertible Notes Payable, Current					$ 1,188,165
Conversion Price Per Unit (in Dollars per share) | $ / shares			$ 0.84
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares		$ 1.50	2.50
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares		$ 0.84	$ 0.84
Debt Conversion, Original Debt, Amount		$ 110,000	$ 110,000
Debt Conversion, Converted Instrument, Units Issued (in Shares) | shares			130,953
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | shares		130,953
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | shares			130,953
CEO and President [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Number of Shares Per Unit					1
Number of Warrants Per Unit					1
CEO and President [Member] | Convertible Notes Payable [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Conversion Price Per Unit (in Dollars per share) | $ / shares					$ 0.45
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares					$ 2.50
Deferred Compensation [Member] | President [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Convertible Notes Payable, Current					$ 755,468
Deferred Compensation [Member] | Chief Executive Officer [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Convertible Notes Payable, Current					1,034,000
Accrued Interest [Member] | President [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Convertible Notes Payable, Current					98,848
Accrued Interest [Member] | Chief Executive Officer [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Convertible Notes Payable, Current					154,165
The 2015 Convertible Notes [Member] | Convertible Debt [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Number of Shares Per Unit		1
Conversion Price Per Unit (in Dollars per share) | $ / shares		$ 0.50
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares		$ 1
Debt Instrument, Interest Rate, Stated Percentage				4.00%
The 2015 Convertible Notes [Member] | Convertible Debt [Member] | President [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Convertible Notes Payable		$ 775,520
Interest Payable		15,002
The 2015 Convertible Notes [Member] | Convertible Debt [Member] | President [Member] | Transferred Balances [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Convertible Notes Payable		760,518
The 2015 Convertible Notes [Member] | Convertible Debt [Member] | Chief Executive Officer [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Convertible Notes Payable		1,493,436
Deferred Compensation Arrangement with Individual, Recorded Liability		239,250
Interest Payable		28,890
The 2015 Convertible Notes [Member] | Convertible Debt [Member] | Chief Executive Officer [Member] | Transferred Balances [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Convertible Notes Payable		1,188,166
The 2015 Convertible Notes [Member] | Convertible Debt [Member] | Chief Executive Officer [Member] | Loan [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Interest Payable		37,130
The 2015 Convertible Notes [Member] | Convertible Debt [Member] | Executive Vice President [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Convertible Notes Payable		385,752			378,290
Deferred Compensation Arrangement with Individual, Recorded Liability					243,750
Interest Payable		$ 7,462
The 2015 Convertible Notes [Member] | Convertible Debt [Member] | Executive Vice President [Member] | Retroactive Compensation [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Deferred Compensation Arrangement with Individual, Recorded Liability					120,000
The 2015 Convertible Notes [Member] | Convertible Debt [Member] | Deferred Compensation, Excluding Share-based Payments and Retirement Benefits [Member] | Executive Vice President [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Interest Payable					$ 14,540
Maximum [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares		$ 3.10
Maximum [Member] | CEO and President [Member] | Convertible Notes Payable [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares					$ 1.25
Minimum [Member]
Note 8 - Convertible Notes Payable - Affiliates (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares		$ 0.75
Sale of Stock, Price Per Share (in Dollars per share) | $ / shares					$ 0.45

Note 9 - Stockholders' Equity36

Note 9 - Stockholders' Equity (Details)	Jul. 01, 2014$ / sharesshares	Jan. 31, 2015USD ($)$ / sharesshares	Mar. 31, 2015$ / sharesshares	Jun. 30, 2015USD ($)$ / shares$ / itemshares	Jun. 30, 2014USD ($)$ / sharesshares	Jun. 30, 2013shares	Jun. 30, 2012shares	Dec. 31, 2014
Note 9 - Stockholders' Equity (Details) [Line Items]
Common Stock Voting Rights Votes Per Share				1
Treasury Stock, Number of Shares Held				704,309
Stock Issued During Period, Shares, Issued for Services				45,647	360,066
Stock Issued During Period, Value, Issued for Services (in Dollars) | $				$ 41,028	$ 307,102
Stock Issued During Period, Shares, Conversion of Convertible Securities					250,000
Proceeds from Issuance of Common Stock (in Dollars) | $				26,250	$ 944,400
Stock Issued During Period, Value, New Issues (in Dollars) | $				26,250	967,575
Sale of Units, Value (in Dollars) | $				900,000
Interest Expense (in Dollars) | $				373,705	$ 403,410
Induced Conversion of Convertible Debt Expense (in Dollars) | $				9,593
Proceeds from Warrant Exercises (in Dollars) | $				$ 74,690
Subscription Agreement, Warrants Agreed to Exercise				12,500
Subscription Agreement, Warrants Agreed to Exercise, Subscription Receivable (in Dollars) | $				$ 13,125
Class of Warrant or Right, Outstanding				9,500,000
Weighted Average Exercise Price for Outstanding Warrants (in Dollars per share) | $ / shares				$ 1.44
Weighted Average Remaining Contractual Life for Outstanding Warrants				4 years 36 days
Modification of Warrants (in Dollars) | $				$ 230,636
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				957,500	97,725
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period				802,500	900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period					200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars) | $				$ 476,075	$ 54,022
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars) | $				$ 50,466
Subscription Agreement [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Sale of Units Price Per Unit Issued (in Dollars per Item) | $ / item				0.50
Number of Shares Per Unit				1
Number of Warrants Per Unit				1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares				$ 0.75
Sale of Units Number of Units Issued				1,800,000
Sale of Units, Value (in Dollars) | $				$ 900,000
Warrant Fair Value Price Per Share (in Dollars per share) | $ / shares				$ 0.05
Adjustments to Additional Paid in Capital, Warrant Issued (in Dollars) | $				$ 34,826
Adjustments to Additional Paid in Capital, Other (in Dollars) | $				$ 865,174
Subscription Agreement to Exercise 12,500 Warrants [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares				$ 1.05
President [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, Other						120,000	120,000
Certain Brokers [Member] | Subscription Agreement [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares				$ 0.75
Payments for Commissions (in Dollars) | $				$ 61,522
Class of Warrant or Right, Issued During Period				123,044
Warrant Fair Value Price Per Share (in Dollars per share) | $ / shares				$ 0.05
Interest Expense (in Dollars) | $				$ 6,152
CEO and Shareholder [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares				$ 0.85	$ 0.85
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				67,500	105,000
Fair Value per Share for Warrants (in Dollars per share) | $ / shares				$ 0.10	$ 0.10
Series B Preferred Stock [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Preferred Stock, Shares Outstanding	200			200	200
Preferred Stock, Par or Stated Value Per Share (in Dollars per share) | $ / shares	$ 0.01			$ 0.01	$ 0.01
Preferred Stock, Redemption Price Per Share (in Dollars per share) | $ / shares	$ 2
Preferred Stock, Dividend Rate, Percentage	2.50%
Convertible Preferred Stock, Redemption, Period	3 years
Dividends, Preferred Stock (in Dollars) | $				$ 2,000	$ 2,000
Dividends Payable (in Dollars) | $				$ 8,000
Restricted Common Stock [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Share Price (in Dollars per share) | $ / shares					$ 0.75
Stock Issued During Period, Shares, New Issues					592,534
Proceeds from Issuance of Common Stock (in Dollars) | $					$ 474,400
Stock Issued for Accounts Payable [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, Other					13,369
Stock Issued During Period, Value, Other (in Dollars) | $					$ 19,940
Net Proceeds [Member] | Restricted Common Stock [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Proceeds from Issuance of Common Stock (in Dollars) | $					$ 467,575
Subscription Agreement [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Share Price (in Dollars per share) | $ / shares					$ 0.75
Stock Issued During Period, Shares, New Issues					266,667
Warrants Expire March 31,2015 [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Extension of Expiration Date, Number of Warrants				985,833
Modification of Warrants (in Dollars) | $				$ 986
Warrants Expire June 30,2015 [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Extension of Expiration Date, Number of Warrants				1,260,833
Modification of Warrants (in Dollars) | $				$ 6,061
Warrant Issuances [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Interest Expense, Other (in Dollars) | $				$ 6,750	$ 10,500
Subscriptions Receivable [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues					40,000
Stock Issued During Period, Value, New Issues (in Dollars) | $					$ 30,000
Restricted Stock [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Share Price (in Dollars per share) | $ / shares				$ 0.75	$ 1.25
Stock Issued During Period, Shares, New Issues				35,000	400,000
Proceeds from Issuance of Common Stock (in Dollars) | $				$ 26,250
Restricted Stock [Member] | Subscription Agreement [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares				$ 0.75
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				900,000
Restricted Stock [Member] | Net Proceeds [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Proceeds from Issuance of Common Stock (in Dollars) | $					$ 500,000
Exercise Bonus [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Outstanding				6,759,500
Percent of Exercise Price to Be Offset					75.00%
Expired [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares					$ 2
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					25,000
Employee Stock Option [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Allocated Share-based Compensation Expense (in Dollars) | $				$ 501,609	$ (204,257)
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				22,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				957,500	97,725
Employee Stock Option [Member] | Executive Vice Chairman [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Allocated Share-based Compensation Expense (in Dollars) | $					$ 210,513
Employees and Consultants [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Value, Issued for Services (in Dollars) | $					307,102
President [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Value, Conversion of Units (in Dollars) | $					187,500
Debt Conversion, Original Debt, Amount (in Dollars) | $		$ 106,099		$ 106,099	$ 187,500
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares		$ 0.45			$ 0.75
Stock Issued During Period, Shares, New Issues						75,000
Number of Shares Per Unit				1
Number of Warrants Per Unit				1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares			$ 1.50	$ 1.50	2.50
Conversion Price Per Unit (in Dollars per share) | $ / shares				$ 0.45	$ 0.75
Debt Conversion, Converted Instrument, Units Issued		235,775		235,775
Debt Conversion, Converted Instrument, Warrants or Options Issued					250,000
Extension of Expiration Date, Number of Warrants				1,883,324
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			150,000
President [Member] | Subscription Agreement [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Sale of Units Number of Units Issued		12,561		12,561
Sale of Units, Value (in Dollars) | $		$ 6,280		$ 6,280
Chief Executive Officer [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities				130,953
Debt Conversion, Original Debt, Amount (in Dollars) | $				$ 110,000	$ 110,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares				$ 0.84	$ 0.84
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares				$ 1.50	2.50
Conversion Price Per Unit (in Dollars per share) | $ / shares					$ 0.84
Debt Conversion, Converted Instrument, Units Issued					130,953
Debt Conversion, Converted Instrument, Warrants or Options Issued					130,953
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				450,000
Chief Executive Officer [Member] | Warrants Expiration Extended until December 31, 2020 [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Extension of Expiration Date, Number of Warrants				3,906,953
President and Various Consultants [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Deferred Compensation Converted to Common Stock, Amount (in Dollars) | $				$ 80,780
Deferred Compensation Converted to Common Stock, Shares				99,523
CEO and President [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Number of Shares Per Unit								1
Number of Warrants Per Unit								1
Extension Agreement, Maximum Exercise Price Established (in Dollars per share) | $ / shares				$ 1.50
Modification of Warrants (in Dollars) | $				$ 223,589
Former Employee [Member] | Employee Stock Option [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Allocated Share-based Compensation Expense (in Dollars) | $				11,783	$ 97,125
CEO, President, and Executive Vice Chairman [Member] | Employee Stock Option [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Allocated Share-based Compensation Expense (in Dollars) | $				$ 357,500
Subscriptions Receivable [Member] | Restricted Stock [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues				40,000	20,000
Stock Issued During Period, Value, New Issues (in Dollars) | $				$ 30,000	$ 25,000
Certain Warrants with Expiry Dates On or Before December 31, 2015 [Member] | For the Period from May 13, 2015 through June 30, 2015 [Member] | Subscription Agreement [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares				$ 1.05
Class of Warrant or Right, Offering Period, Extension				15 days
Induced Conversion of Convertible Debt Expense (in Dollars) | $				$ 9,593
Class of Warrant or Right, Exercised During Period				71,133
Common Stock, Shares Issued upon Exercise of Warrants				71,133
Proceeds from Warrant Exercises (in Dollars) | $				$ 74,690
Warrants Issued Relating to Consulting Agreement [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					35,465
Fair Value per Share for Warrants (in Dollars per share) | $ / shares					$ 0.10
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					5 years
Allocated Share-based Compensation Expense (in Dollars) | $					$ 3,546
Warrants Issued During the Year Ended June 30, 2014 [Member] | Exercise Bonus [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Issued During Period					35,465
Warrants Issued Before Fiscal Year 2014 [Member] | Exercise Bonus [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Issued During Period						38,786
Minimum [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Share Price (in Dollars per share) | $ / shares				$ 0.43
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares				0.75
Minimum [Member] | Stock Issued for Accounts Payable [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Share Price (in Dollars per share) | $ / shares					$ 1.46
Minimum [Member] | Employees and Consultants [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Share Price (in Dollars per share) | $ / shares					0.75
Minimum [Member] | President and Various Consultants [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Deferred Compensation Converted to Common Stock, Conversion Rate (in Dollars per share) | $ / shares				0.72
Minimum [Member] | Warrants Issued Relating to Consulting Agreement [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares					1.12
Maximum [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Share Price (in Dollars per share) | $ / shares				1.22
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares				$ 3.10
Maximum [Member] | Stock Issued for Accounts Payable [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Share Price (in Dollars per share) | $ / shares					1.51
Maximum [Member] | Employee Stock Option [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Maximum [Member] | Employees and Consultants [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Share Price (in Dollars per share) | $ / shares					1.85
Maximum [Member] | President and Various Consultants [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Deferred Compensation Converted to Common Stock, Conversion Rate (in Dollars per share) | $ / shares				$ 1.24
Maximum [Member] | Warrants Issued Relating to Consulting Agreement [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares					$ 1.71

Note 9 - Stockholders' Equity37

Note 9 - Stockholders' Equity (Details) - Stock Options - Valuation Assumptions	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Note 9 - Stockholders' Equity (Details) - Stock Options - Valuation Assumptions [Line Items]
Volatility	76.00%	54.00%
Dividend yield	0.00%	0.00%
Risk-free interest rate	1.55%	0.95%
Expected term (years)	6 years 36 days	3 years 105 days
Minimum [Member]
Note 9 - Stockholders' Equity (Details) - Stock Options - Valuation Assumptions [Line Items]
Volatility	74.00%	49.00%
Risk-free interest rate	0.51%	0.59%
Expected term (years)	2 years	2 years 229 days
Maximum [Member]
Note 9 - Stockholders' Equity (Details) - Stock Options - Valuation Assumptions [Line Items]
Volatility	80.00%	65.00%
Risk-free interest rate	1.79%	1.69%
Expected term (years)	10 years	4 years 244 days

Note 9 - Stockholders' Equity38

Note 9 - Stockholders' Equity (Details) - Stock Options Activity - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Stock Options Activity [Abstract]
Options Outstanding	4,413,870	4,258,870	5,261,145
Options Outstanding, Weighted-Average Exercise Price	$ 1.88	$ 2.81	$ 2.84
Options Outstanding, Weighted-Average Remaining Contractual Life	4 years 109 days	3 years 73 days	4 years
Options Outstanding, Aggregate Intrinsic Aggregate	$ 398,250
Exercisable at June 30, 2015	4,313,870
Exercisable at June 30, 2015	$ 1.91
Exercisable at June 30, 2015	4 years 73 days
Exercisable at June 30, 2015	$ 344,250
Granted	957,500	97,725
Granted, Weighted-Average Exercise Price	$ 0.74	$ 1.35
Exercised		0
Exercised, Weighted-Average Exercise Price		$ 0
Forfeited		(200,000)
Forfeited, Weighted-Average Exercise Price		$ 3
Expired	(802,500)	(900,000)
Expired, Weighted-Average Exercise Price	$ 2.7	$ 2.84

Note 9 - Stockholders' Equity39

Note 9 - Stockholders' Equity (Details) - Nonvested Share Activity - $ / shares	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Nonvested Share Activity [Abstract]
Nonvested at July 1, 2014	0
Nonvested at July 1, 2014	$ 0
Granted	957,500	97,725
Granted	$ 0.58
Vested	(857,500)
Vested	$ (0.56)
Nonvested at June 30, 2015	100,000	0
Nonvested at June 30, 2015	$ 0.76	$ 0

Note 9 - Stockholders' Equity40

Note 9 - Stockholders' Equity (Details) - Allocation of Recognized Period Costs - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
General and Administrative Expense [Member]
General and administrative:
Stock-based employee compensation expense	$ 972,137	$ 315,119
Research and Development Expense [Member]
General and administrative:
Stock-based employee compensation expense	122,672	(116,739)
Employee Stock Option [Member]
General and administrative:
Stock-based employee compensation expense	501,609	(204,257)
Employee Stock Option [Member] | General and Administrative Expense [Member]
General and administrative:
Stock-based employee compensation expense	378,937	(87,517)
Change in fair value from modification of Plan terms	369,283	307,638
Employee Stock Option [Member] | Research and Development Expense [Member]
General and administrative:
Stock-based employee compensation expense	122,672	(116,739)
Individual Employee [Member] | General and Administrative Expense [Member]
General and administrative:
Stock-based employee compensation expense		$ 94,998
Modification of Warrants [Member] | General and Administrative Expense [Member]
General and administrative:
Change in fair value from modification of Plan terms	$ 223,917

Note 10 - Gain on Extinguishm41

Note 10 - Gain on Extinguishment of Liabilities (Details)	12 Months Ended
	Jun. 30, 2014USD ($)
Gain On Extinguishment Of Liabilities [Abstract]
Gains (Losses) on Extinguishment of Debt	$ 20,113

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details) - Jun. 30, 2015 - USD ($)	Total
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$ 50,194,000
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	100.00%

Note 11 - Income Taxes (Detai43

Note 11 - Income Taxes (Details) - Reconciliation Schedule of Federal Income Tax Benefits - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Reconciliation Schedule of Federal Income Tax Benefits [Abstract]
Expected income tax benefit at statutory rate	$ (1,918,000)	$ (1,959,000)
State taxes, net of federal benefit	(173,000)	(177,000)
Permanent differences and other	(19,000)	(19,000)
Change in valuation allowance	2,110,000	2,155,000
Income tax benefit	$ 0	$ 0

Note 11 - Income Taxes (Detai44

Note 11 - Income Taxes (Details) - Table of Estimated Deferred Tax Assets and Liabilities - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Table of Estimated Deferred Tax Assets and Liabilities [Abstract]
NOLs – noncurrent	$ 19,083,000	$ 18,392,000
Stock-based compensation - current	5,255,000	4,832,000
Property and equipment – noncurrent	1,390,000	741,000
Deferred compensation - noncurrent	1,383,000	1,036,000
	27,111,000	25,001,000
Valuation allowance	(27,111,000)	(25,001,000)
Net deferred tax assets	$ 0	$ 0

Note 12 - 401(k) Plan (Details)

Note 12 - 401(k) Plan (Details)	12 Months Ended
	Jun. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Defined Contribution Pension and Other Postretirement Plans, Minimum Age	21 years

Note 13 - Commitments and Con46

Note 13 - Commitments and Contingencies (Details)

Sep. 25, 2014USD ($)

Mar. 31, 2015USD ($)$ / sharesshares

Mar. 31, 2015USD ($)$ / sharesshares

Dec. 31, 2014USD ($)$ / shares

Aug. 31, 2012USD ($)

Jun. 30, 2015USD ($)$ / sharesshares

Jun. 30, 2014USD ($)$ / sharesshares

Jun. 30, 2013USD ($)$ / sharesshares

Jul. 14, 2012USD ($)

Jun. 30, 2012USD ($)shares

Mar. 31, 2015USD ($)$ / shares

Feb. 28, 2014USD ($)

Jun. 30, 2014USD ($)$ / sharesshares

Sep. 18, 2015$ / shares

Jan. 31, 2015$ / shares

Dec. 13, 2014

Sep. 30, 2014shares

Note 13 - Commitments and Contingencies (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in Shares) | shares

200,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | shares

957,500

97,725

Due to Related Parties, Current

$ 382,458

$ 382,458

Deferred Compensation Liability, Current

$ 839,288

$ 716,734

$ 716,734

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares) | shares

4,413,870

4,258,870

5,261,145

4,258,870

Class of Warrant or Right, Outstanding (in Shares) | shares

9,500,000

Stock Issued During Period, Value, New Issues

$ 26,250

$ 967,575

Subsequent Event [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 1.05

Stock Bonus [Member] | Stock Bonus Payable Upon Stock Price of $10.00 per Share [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Share Price (in Dollars per share) | $ / shares

$ 10

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares) | shares

40,000

Exercise Bonus [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares) | shares

2,945,000

Class of Warrant or Right, Outstanding (in Shares) | shares

6,759,500

Morris Versus Bion [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Increase (Decrease) in Deferred Compensation and Severance Pay

$ (271,000)

Pennvest Loan [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Loss Contingency, Damages Sought, Value

$ 8,137,117

Maximum [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Share Price (in Dollars per share) | $ / shares

$ 1.22

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 3.10

Chief Executive Officer [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 1.50

Accrued Interest on Deferred Compensation

$ 74,250

Deferred Compensation Liability, Current

$ 187,542

CEO and President [Member] | Exercise Bonus [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Execution Bonus as a Percentage of Exercised Options and Warrants

50.00%

Contingent Stock Bonus, Percentage Threshold for Issuance

50.00%

Extension of Exercise Period, Annual Payment per Option or Warrant (in Dollars per share) | $ / shares

$ 0.05

CEO and President [Member] | Maximum [Member] | Exercise Bonus [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Extension of Exercise Period

5 years

Employment Termination Severance Pay [Member] | Morris Versus Bion [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Loss Contingency, Damages Sought, Value

90,000

Accrued Employment Obligations [Member] | Morris Versus Bion [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Loss Contingency, Damages Sought, Value

87,000

President [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Convertible Notes Payable

854,316

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 0.75

$ 0.75

$ 0.45

Number of Warrants Per Unit

1

Monthly Officers' Cash Compensation

$ 18,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | shares

150,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 1.50

$ 1.50

$ 1.50

2.50

$ 1.50

2.50

Stock Issued During Period, Shares, New Issues (in Shares) | shares

75,000

President [Member] | Stock Bonus [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in Shares) | shares

150,000

Chief Executive Officer [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 0.84

0.84

0.84

Monthly Officers' Cash Compensation

$ 31,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | shares

450,000

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 1.50

$ 2.50

$ 2.50

Due to Related Parties, Current

279,000

Unreimbursed Expense

116,277

Chief Executive Officer [Member] | Stock Bonus [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in Shares) | shares

250,000

Executive Vice Chairman [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 1

Unreimbursed Expense

15,956

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | shares

7,978

Deferred Compensation Liability, Current and Noncurrent

394,246

Deferred Compensation Liability, Current

$ 120,000

Executive Vice Chairman [Member] | Stock Bonus [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in Shares) | shares

25,000

Extension Agreement One [Member] | President [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Monthly Officers' Compensation

$ 20,000

Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | shares

90,000

Extension Agreement One [Member] | President [Member] | Initial Amounts [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Allocated Share-based Compensation Expense

$ 240,300

Extension Agreement One [Member] | Chief Executive Officer [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Monthly Officers' Compensation

$ 26,000

Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | shares

300,000

Extension Agreement One [Member] | Chief Executive Officer [Member] | Stock Bonus [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Allocated Share-based Compensation Expense

$ 795,000

Extension Agreement One [Member] | Tranch 1 [Member] | President [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | shares

45,000

Extension Agreement One [Member] | Tranch 1 [Member] | Chief Executive Officer [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | shares

100,000

Extension Agreement One [Member] | Tranch 2 [Member] | President [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | shares

45,000

Extension Agreement One [Member] | Tranch 2 [Member] | Chief Executive Officer [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | shares

100,000

Extension Agreement One [Member] | Tranch 3 [Member] | Chief Executive Officer [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | shares

100,000

Extension Agreement 2 [Member] | President [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Monthly Officers' Compensation

$ 14,000

$ 21,000

Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | shares

150,000

Allocated Share-based Compensation Expense

$ 292,500

Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants

$ 25,000

Stock Issued During Period, Shares, Conversion of Units (in Shares) | shares

250,000

Deferred Compensation Arrangement with Individual, Exercise Price (in Dollars per share) | $ / shares

$ 2.10

Extension Agreement 2 [Member] | President [Member] | Stock Bonus Payable Upon Stock Price of $10.00 per Share [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares) | shares

100,000

Share Price (in Dollars per share) | $ / shares

$ 10

Extension Agreement 2 [Member] | Chief Executive Officer [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Monthly Officers' Compensation

$ 26,000

Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | shares

300,000

300,000

Allocated Share-based Compensation Expense

$ 585,000

Extension Agreement 2 [Member] | Tranch 1 [Member] | President [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | shares

75,000

Extension Agreement 2 [Member] | Tranch 1 [Member] | Chief Executive Officer [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | shares

150,000

150,000

Extension Agreement 2 [Member] | Tranch 2 [Member] | President [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | shares

75,000

Extension Agreement 2 [Member] | Tranch 2 [Member] | Chief Executive Officer [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | shares

150,000

150,000

Extension Agreement Three [Member] | Deferral of Extension 1 Tranch 1 [Member] | Chief Executive Officer [Member] | Subsequent Event [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | shares

100,000

Extension Agreement Three [Member] | Deferral of Extension 2 Tranch 1 [Member] | Chief Executive Officer [Member] | Subsequent Event [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Common Stock, Capital Shares Reserved for Future Issuance (in Shares) | shares

150,000

Settled, Mr. Morris [Member] | Morris Versus Bion [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Payments for Legal Settlements

$ 20,000

Stock Issued During Period, Shares, New Issues (in Shares) | shares

10,000

Stock Issued During Period, Value, New Issues

$ 6,600

Settled, Mr. Morris' Attorney [Member] | Morris Versus Bion [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Payments for Legal Settlements

$ 10,000

New Smith Note [Member] | President [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Convertible Notes Payable

$ 760,520

New Smith Note [Member] | President [Member] | Convertible Debt [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Debt Instrument, Interest Rate Reduction, Percentage

50.00%

Debt Instrument, Interest Rate, Stated Percentage

8.00%

4.00%

Debt Instrument, Convertible Conversion Price, Incease, Percentage

11.00%

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 0.45

$ 0.50

Accrued Interest on Deferred Compensation

$ 0.75

Number of Warrants Per Unit

1

Cash Note [Member] | Chief Executive Officer [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ / shares

$ 1

Debt Instrument, Face Amount

$ 395,277

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | shares

592,916

Mr. Bassani [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Convertible Notes Payable

$ 1,464,545

Mr. Bassani [Member] | Chief Executive Officer [Member] | Convertible Debt [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Debt Instrument, Interest Rate Reduction, Percentage

50.00%

Debt Instrument, Interest Rate, Stated Percentage

4.00%

8.00%

Debt Instrument, Convertible Conversion Price, Incease, Percentage

11.00%

Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ / shares

$ 0.45

$ 0.50

Number of Warrants Per Unit

1

Number of Warrants Per Unit, Reduction, Percentage

75.00%

Number of Units Per Warrant

4

New Promissory Note [Member] | Executive Vice Chairman [Member]

Note 13 - Commitments and Contingencies (Details) [Line Items]

Debt Instrument, Face Amount

$ 15,956

Note 13 - Commitments and Con47

Note 13 - Commitments and Contingencies (Details) - Summary of Outstanding Contingent Stock Bonuses - $ / shares	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Note 13 - Commitments and Contingencies (Details) - Summary of Outstanding Contingent Stock Bonuses [Line Items]
Number of shares	4,413,870	4,258,870	5,261,145
Stock Bonus [Member] | Stock Bonus Payable Upon Stock Price of $5.00 per Share [Member]
Note 13 - Commitments and Contingencies (Details) - Summary of Outstanding Contingent Stock Bonuses [Line Items]
Target Price per share	$ 5
Number of shares	50,000
Stock Bonus [Member] | Stock Bonus Payable Upon Stock Price of $10.00 per Share [Member]
Note 13 - Commitments and Contingencies (Details) - Summary of Outstanding Contingent Stock Bonuses [Line Items]
Target Price per share	$ 10
Number of shares	40,000
Stock Bonus [Member] | Stock Bonus Payable Upon Stock Price of $20.00 per Share [Member]
Note 13 - Commitments and Contingencies (Details) - Summary of Outstanding Contingent Stock Bonuses [Line Items]
Target Price per share	$ 20
Number of shares	27,500

Note 14 - Subsequent Events (De

Note 14 - Subsequent Events (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 18, 2015	Jun. 30, 2015	Jun. 30, 2014	Sep. 08, 2015
Note 14 - Subsequent Events (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services (in Shares)		45,647	360,066
Stock Issued During Period, Value, Issued for Services		$ 41,028	$ 307,102
Proceeds from Warrant Exercises		$ 74,690
Subsequent Event [Member]
Note 14 - Subsequent Events (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1.05
Class of Warrant or Right, Exercised During Period (in Shares)	278,394
Stock Issued During Period, Shares, Warrants Exercised (in Shares)	278,394
Proceeds from Warrant Exercises	$ 187,300
Subsequent Event [Member] | Employees and Consultants [Member]
Note 14 - Subsequent Events (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services (in Shares)	29,934
Stock Issued During Period, Value, Issued for Services	$ 26,000
Subsequent Event [Member] | Consultants [Member]
Note 14 - Subsequent Events (Details) [Line Items]
Stock Issued During Period, Value, Conversion of Deferred Compensation	$ 88,800
Stock Issued During Period, Shares, Conversion of Deferred Compensation (in Shares)	109,715
Subsequent Event [Member] | Chairman and President [Member]
Note 14 - Subsequent Events (Details) [Line Items]
Stock Issued During Period, Value, Conversion of Deferred Compensation	$ 82,900
Stock Issued During Period, Shares, Conversion of Deferred Compensation (in Shares)	99,159
Collateralized Promissory Note [Member] | Subsequent Event [Member]
Note 14 - Subsequent Events (Details) [Line Items]
Notes Issued	$ 105,000
Debt Instrument, Interest Rate, Stated Percentage	4.00%
Chief Executive Officer [Member]
Note 14 - Subsequent Events (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 1.50	$ 2.50
Notes Payable, Related Parties		$ 316,131
Debt Instrument, Convertible, Conversion Price (in Dollars per share)		$ 0.84	$ 0.84
Chief Executive Officer [Member] | Subsequent Event [Member]
Note 14 - Subsequent Events (Details) [Line Items]
Notes Payable, Related Parties				$ 405,831
Executive Vice Chairman [Member]
Note 14 - Subsequent Events (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 1
Executive Vice Chairman [Member] | Subsequent Event [Member]
Note 14 - Subsequent Events (Details) [Line Items]
Notes Payable, Related Parties				16,382
Majority Shareholder [Member]
Note 14 - Subsequent Events (Details) [Line Items]
Notes Payable, Related Parties		$ 80,764
Majority Shareholder [Member] | Subsequent Event [Member]
Note 14 - Subsequent Events (Details) [Line Items]
Notes Payable, Related Parties				$ 82,921
CEO, Chairman and President, and Shareholder [Member] | Subsequent Event [Member]
Note 14 - Subsequent Events (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				4.00%
Debt Instrument, Convertible, Conversion Price (in Dollars per share)				$ 0.60